SARS-COV-2 5'UTR sequences and linkage thereof to coding sequences

Incorporating SARS-CoV-2 leader sequences in the 5'UTR of mRNA molecules addresses the challenges of translation efficiency and stability, enhancing ribosome recruitment and reducing production costs by optimizing mRNA design for improved translation and stability.

WO2025012671A1PCT designated stage expired Publication Date: 2025-01-16INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2023/000504
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-07-07
Publication Date
2025-01-16

AI Technical Summary

Technical Problem

Current methods for increasing mRNA stability and reducing immunogenic response while enhancing translation efficiency are inadequate, particularly for SARS-CoV-2 mRNA, which poses challenges in medical applications due to variable translation efficiencies and high costs of production.

Method used

Incorporating specific SARS-CoV-2 leader sequences in the 5'UTR of mRNA molecules to optimize ribosome recruitment and translation initiation, combined with cap-dependent mechanisms and poly-A tail structures, to enhance translational efficiency and stability.

Benefits of technology

The approach significantly improves the translation efficiency of SARS-CoV-2 mRNA, achieving high ribosome recruitment despite complex RNA structures and short upstream reading frames, and reduces production costs by optimizing mRNA design.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000010_0001
    Figure IMGF000010_0001
  • Figure IMGF000064_0001
    Figure IMGF000064_0001
  • Figure IMGF000076_0001
    Figure IMGF000076_0001
Patent Text Reader

Abstract

Using a several approaches, to study translation of SARS-CoV- genomic RNA (gRNA) inventors have subsequently identified unusual structural features in 5'UTR of gRNA. All these unusual structural features can have a great impact on the translational efficiency of the genomic and sub-genomic SARS-CoV-2 RNAs and this set the rationale for this invention. By using a series of in vitro and ex vivo functional translational assays, inventors have investigated and compared translation of all SARS-CoV-2 transcripts. The data show some unexpected characteristics of the genomic RNA, which is extremely efficient to recruit ribosomes for protein synthesis in all systems assayed despite its length. Accordingly the invention relates to mRNA harbouring 5'UTR sequences allowing for high translation efficiencies of RNA molecules containing them. Moreover, the present invention relates to a pharmaceutical and vaccinal composition comprising the described RNA molecule as well as to the use of the described UTRs for translating a coding region of an RNA molecule into a polypeptide or a protein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] SARS-COV-2 5'UTR SEQUENCES AND LINKAGE THEREOF TO CODING SEQUENCES

[0002] FIELD OF THE INVENTION:

[0003] The invention relates to mRNA harbouring 5’UTR sequences allowing for high translation efficiencies of RNA molecules containing them. Further, the present invention relates to vectors comprising such a RNA molecule and to host cells comprising such a vector. Moreover, the present invention relates to a pharmaceutical and vaccinal composition comprising the described RNA molecule and optionally a pharmaceutically acceptable carrier as well as to the use of the described UTRs for translating a coding region of an RNA molecule into a polypeptide or a protein encoded by said coding region.

[0004] BACKGROUND OF THE INVENTION:

[0005] In eukaryotes, translation is a highly regulated step of gene expression in which mRNAs are decoded by ribosomes into proteins. This mechanism can be divided into four steps: initiation, elongation, termination and ribosome recycling. The initiation process is the ratelimiting step that promotes the formation of ribosomal complexes at the initiation codon [1], The majority of the cellular and viral mRNAs use the scanning model to engage the ribosome on the mRNAs. This starts with the formation of a 43 S complex, which is composed of the 40S small ribosomal subunit associated with several eukaryotic initiation factors (elFs), notably elFl, elFlA, eIF3 and the ternary complex (TC) [1,2]. This TC results in the association of eIF2 with a GTP molecule and the Met-tRNAiMet[3], Most eukaryotic mRNAs are capped at their 5’ extremity and polyadenylated at their 3' end in order to ensure integrity, stability and efficient translation of the mRNA. The cap structure consists of a 7-methylguanylate residue connected to the mRNA via an unusual 5' to 5' triphosphate linkage [4], The cap interacts with the eIF4F complex, which is composed of the cap-binding protein eIF4E, the scaffold protein eIF4G and the RNA helicase eIF4A. The eIF4F complex plays a crucial role during initiation because it establishes a physical and functional link between the mRNA (through a cap-eIF4E interaction) and the 43S complex (through an eIF4G-eIF3 interaction) [5-7], Once bound to the 5 ’end of the mRNA, the 43 S complex scans the 5' untranslated region (UTR) in a 5’ to 3’ direction to reach the cognate AUG start codon. This is catalyzed by the RNA and ATP- dependent helicase activity of eIF4A, which unfolds the RNA structures encountered within the 5'UTR. Recognition of the translation initiation site (TIS) is ensured by a perfect base pairing between the AUG codon and the anticodon of the tRNAiMet, which triggers GTP hydrolysis and elFs release, followed by association of the 40S ribosomal subunit with the 60S ribosomal subunit to form the 80S ribosome competent for elongation [1,2,8].

[0006] The efficiency of translation initiation is largely regulated by both eIF2 and eIF4F [9- 11], but the intrinsic characteristics of the mRNA, such as length, RNA folding and upstream AUG codons, can also modulate the flow and quantity of ribosomes on the transcript

[0012] , In general, initiation on most eukaryotic mRNAs adheres to the first AUG rule, in which the AUG triplet nearest the 5'end is the beginning of the reading frame [13-16], It is noteworthy that the nucleotides that surround the initiation codon are critical for efficient recognition with the following sequence — GCCA / GCCAUGG — (SEQ ID N° 13) being optimal and defined as the Kozak context [13,14], It has been reported that the nucleotides upstream of the AUG codon, especially the purine at position -3 (according to the position of the AUG codon), are important for efficient initiation [13,17-19], UV cross-linking experiments in the 48S pre-initiation complex (PIC) strongly suggested an interaction between eIF2a and the -3 purine

[0020] , This was confirmed later by cryo-EM analyses of PIC indicating that the arginine residues (Arg55 and Arg57) of eIF2a are located within close proximity of the mRNA nucleotides upstream to the AUG codon, including the -3 position

[0021] , These data are consistent with the role of eIF2 in AUG codon recognition

[0022] , However, the influence of the nucleotide in the +4 position is rather controversial. Some experiments showed that mutation of the guanosine reduces translation initiation efficiency

[0013] , but it was shown by analysis of all possible combinations using a FACS-seq approach that the +4G was not always the optimum

[0023] , In addition, an alternative explanation was suggested and it was based on the amino acid constraint on the second codon that participates in post-translational modification, such as the N-terminus methionine excision [24,25], Thus, according to the robustness of this Kozak context, the AUG codon can be more or less recognized as a translation initiation site or even completely ignored. In addition to these features, the presence of short upstream open reading frames (uORFs) within the 5'UTR can also have an impact on translational efficiency of the main gene due to the fact that some ribosomes will translate these uORFs and then dissociate from the mRNA before reaching the main reading frame [26-28], This is why the presence of these uORFs is often associated with a reduction of production of the main protein product. Interestingly, in some particular physiological conditions, the level of active TC is reduced and this favors the bypass of these uORFs, resulting in efficient translation of the main ORF [29-31], Another key feature of the mRNA that can regulate ribosome recruitment is the RNA structure adopted by the 5'UTR. It is now well known that a thermodynamically stable hairpin structure at the 5 ’end can completely block 43 S complex attachment to the cap structure [32- 36] and it usually requires additional RNA helicases to overcome the energy barrier imposed by these structures [37-39], In some cases, these RNA motifs can serve as anchors for the binding of specific proteins, creating an RNA-protein complex that can arrest the scanning of the 43 S ribosome.

[0007] Several strategies have proven successful both at increasing the stability and reducing the immunogenic response triggered by mRNA administered to cells or organisms. Amongst these is the inclusion of chemically modified nucleotides; Current Opinion in Drug Discovery and Development, 2007, 10:523. Kormann et al. have shown that the replacement of only 25% of uridine and cytidine residues by 2- thiouridine and 5-methyl-cytidine suffices to increase mRNA stability as well as to reduce the activation of innate immunity triggered by externally administered mRNA in vitro (WO2012 / 0195936 Al; W02007024708 A2).

[0008] Although in the prior art there are already described means and methods for increasing the stability of mRNA, reducing the immunogenic response triggered by mRNA administered to cells or organisms and increasing the expression efficiency (i.e., the transcription and / or translation efficiency) there is still a need for improvements, in particular as regards further or alternate means to increase the expression efficiency (i.e., the transcription and / or translation efficiency) since the expression efficiency is an essential parameter for envisaged medical applications because it determines, for example, dosing and the dosing intervals of mRNA drugs and, ultimately, determines the bioavailability of the final product, i.e., the encoded peptide or protein. At the same time, there is a constant need for further decreasing the costs for the production of mRNA drugs, increasing the yield of the produced mRNA molecules.

[0009] Finally, there is a continued need to develop novel strategy for high translation efficiencies of RNA molecules.

[0010] The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

[0068] contains a long and positive RNA genome (gRNA), which is capped and polyadenylated. Once in the cytoplasm, the gRNA is immediately translated into two large polyproteins, ORF la and ORF lab, which generate 16 non-structural proteins (nsp) after proteolytic cleavage. Expression of these non-structural proteins is essential for replication and this starts with the transcription of a full-length negative-sense genomic copy that serves as template for the production of positive-sense genomic RNAs. One of the peculiarities of the coronaviruses is that they harbor a conserved leader sequence located at the 5' end of the transcript that serves as a cv.s-acting element for the transcription of all sub-genomic mRNAs (sgRNA). This leader sequence is added to all sgRNAs through a polymerase template switching that occurs when the viral polymerase encounters the transcriptional regulatory sequence (TRS). The TRS precedes every single viral gene and is called the body TRS (TRS-B), with a conserved core sequence that is thought to hybridize with the leader TRS (TRS-L) [69-71], As a result, all 5'UTRs of SARS- CoV-2 mRNAs (sgRNAs and gRNAs) share an absolutely conserved 75-nucleotide (nt.) stretch, which is called the leader sequence. This leader sequence is then followed by a variable RNA length (from 0 to 190 nt.) that terminates onto an AUG start codon (Figure 1). Viral transcription generates up to nine sgRNAs coding for the structural (S, E, M and N) and accessory (ORF-3a, ORF-6, ORF-7a, ORF-7b and ORF-8) proteins (Figure 1) [71,72], The 5'UTRs of ORF-7a and ORF-8 gRNA are identical and harbor only the leader sequence (Figure 1 and Table 1). The 5'UTRs of ORF-S, ORF-3a, ORF-E and ORF-N are composed of the leader sequence followed by only a few nucleotides (from 1 to 8 nt.) (Figure 1 and Table 1). In contrast, the 5'UTR of ORF-M, ORF-6 and ORF-7b are relatively long, with respective lengths of 119, 230 and 151 nt. including the leader sequence (Figure 1 and Table 1). Thus, every single sgRNA harbors its own 5’UTR and the nucleotide surrounding context of each AUG start codon is also unique (Table 1); these structural features could potentially modulate translational efficiency.

[0011] The 5'UTR of the gRNA is the longest (265 nt.) of all the viral mRNAs and contains five stem-loop structures (SL1 to SL5) that have recently been modelized by chemical probing analyses (Figure 2) [73,74], These SL are critical for replication, RNA synthesis and escape from nspl-mediated translation inhibition [75-81]; however, they could potentially represent hurdles for translation, notably at the level of ribosome recruitment and scanning. Although the viral genome of SARS-CoV-2 is capped and polyadenylated, the translation initiation mechanism used to locate the AUG start co-don inside the SL5 remains undetermined. In particular, one can predict that the high level of RNA secondary structures within the 5’UTR could be a serious hurdle for ribosome scanning and this could suggest another mechanism for translation initiation. Such a hypothesis is also strengthened by the fact that the AUG start codon is located at the vicinity and downstream of a four- way junction structure (Figure 2), a situation that is reminiscent of similar motifs found in some viral IRESes [49,82-85], Last but not least, the SARS-CoV-2 5'UTR also contains an uORF starting at AUG107, which is located within the SL4 (Figure 2) and seems to be used as an initiation site, as suggested by ribosome profiling analyses in infected cells [72,86], Interestingly and curiously, ribosome profiling analyses have also highlighted other uORFs initiating at near-cognate initiation codons [72,86], One is of particular interest because it is located on a CUG codon at position 59 just 10 nt. upstream of the TRS leader, which means that it will be present on all the sgRNAs. However, one should bear in mind that ribosome occupancy observed in ribosome profiling analysis remains only indicative, as it is often difficult to distinguish between a real TIS and the pausing of the 48S preinitiation complex

[0072] ,

[0012] SUMMARY OF THE INVENTION:

[0013] The invention provides an RNA molecule comprising

[0014] (a) a coding region, including a start codon at its 5' end, coding for a polypeptide; and

[0015] (b) directly upstream of said coding sequence a 5’UTR sequence comprising a SARS- COV2 LEADER SEQUENCE (called LS) of SEQ ID N°1 AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUG UAGAUCUGUUCUCUAAACGAAC (LS sequence of ORF7A / ORF8).

[0016] The invention further relates to a nucleic acid molecule encoding the RNA molecule of the invention.

[0017] The invention further relates to a pharmaceutical or vaccinal composition comprising the RNA molecule according to the invention, the nucleic acid molecule according to the invention.

[0018] The invention further relates to a method for translating a coding region of RNA molecule into a polypeptide or a protein encoded by said coding region using an 5’UTR as defined in the invention.

[0019] DETAILED DESCRIPTION OF THE INVENTION:

[0020] Using a several approaches, to study translation of SARS-CoV- genomic RNA (gRNA) inventors have subsequently identified unusual structural features in 5’UTR of gRNA. All these unusual structural features can have a great impact on the translational efficiency of the genomic and sub-genomic SARS-CoV-2 RNAs and this set the rationale for this invention. By using a series of in vitro and ex vivo functional translational assays coupled with specific inhibitors of the cap-dependent mechanism, inventors have investigated and compared translation of all SARS-CoV-2 transcripts. The data show some unexpected characteristics of the genomic RNA, which is extremely efficient to recruit ribosomes for protein synthesis in all systems assayed despite its length, complex RNA structure and the presence of a short upstream reading frame; these translational features are well conserved with the SARS-CoV-1 but less with MERS-CoV.

[0021] The SARS-CoV-2 infection generates up to nine different sub-genomic mRNAs (sgRNAs), in addition to the genomic RNA (gRNA). The 5'UTR of each viral mRNA shares the first 75 nucleotides (nt.) at their 5 'end, called the leader, but differentiates by a variable sequence (0 to 190 nt. long) that follows the leader. As a result, each viral mRNA has its own specific 5'UTR in term of length, RNA structure, uORF and Kozak context; each one of these characteristics could affect mRNA expression. In this invention, inventors have measured and compared translational efficiency of each of the ten viral transcripts. Inventors data show that most of them are very efficiently translated in all translational systems tested. Surprisingly, the gRNA 5'UTR, which is the longest and the most structured, was also the most efficient to initiate translation. This property is conserved in the 5'UTR of SARS-CoV-1 but less in MERS- CoV strain, which could mainly be due to the regulation imposed by the uORF. Interestingly, the translation initiation mechanism on the SARS-CoV-2 gRNA 5'UTR requires the cap structure and the components of the eIF4F complex but showed no dependence in the presence of the poly(A) tail in vitro.

[0022] RNA molecules with 5’UTR according to the invention

[0023] The invention relates to an isolated RNA (Ribonucleic Acid) molecule comprising

[0024] (a) a coding region, including a start codon at its 5' end, coding for a polypeptide; and

[0025] (b) directly upstream of said coding sequence a 5’UTR sequence comprising a SARS-COV2 LEADER SEQUENCE (called LS) of SEQ ID N°1 AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUG UAGAUCUGUUCUCUAAACGAAC (LS sequence of ORF 7a / ORF8). wherein the RNA molecule comprises optionally a poly-A tail at the 3' end.

[0026] In particular embodiment the 5’UTR sequence is selected from the group comprising or consisting of:

[0027] (bl ) an UTR of the sequence : LS (SEQ ID NO: 1 ) (ORF7a- / ORF8 )

[0028] (b2) an UTR of the sequence LS-A (SEQ ID NO:2) (ORF S) (b3) an UTR of the sequence LS-AAACUAAA (SEQ ID NO:3) (ORF N);

[0029] (b4) an UTR of the sequence LS

[0030] UUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACAC UUUGCUUCACACUCAAAAGAAAGACAGA (SEQ ID NO: 4) (ORF 7B);

[0031] (b5) an UTR of the sequence LS-

[0032] GCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCA GGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAAC ACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAG UGACAACAG) (SEQ ID NO: 5) (ORF 6);

[0033] (b6) an UTR of the sequence LS-

[0034] UAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCC) (SEQ ID NO: 6) (ORF M); and

[0035] (b7) an UTR of the sequence LS-UU (SEQ ID NO:7) (ORF E and ORF 3A);

[0036] (b8) an UTR of the sequence LS-

[0037] UUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACG CAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACU CGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAU CAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAG (SEQ ID NO: 8) (ORF 1AB); and or a sequence wherein in said UTR sequence the triplet AUG at position 107-109 of SEQ ID NO 8 is substituted by triplet different from AUG and / or at least one triplet UAAUGA at position, 134-136; 137-139; 251-253; and 262-264 of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA, UAG, UGA (stop codon) ; and (b9) an UTR sequence substantially homologous to the sequence of (bl) to (b8) preferably a sequence at least 80% identical to the sequence of (bl) to (b8).

[0038] In a particular embodiment the triplet AUG at position 107-109 of SEQ ID NO:8 is substituted by a triplet UAA or UUG or CCG.

[0039] The results of the different mutations the triplet AUG at position 107-109 are described in figure 7 and 9. In a particular embodiment at least one the triplet UAA / UGA at position 134-136; 137- 139; 251-253; and 262-264 of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA, UAG, UGA.

[0040] In a particular embodiment all the triplet UAA / UGA at position 134-136; 137-139; 251- 253; and 262-264 of SEQ ID NO: 8 are deleted or substituted by a triplet different from UAA, UAG, UGA

[0041] In a more particular embodiment nucleotides of SEQ ID NO:8 is mutated in at the following position : 136A>C; 137T>A; 139A>T; 140OA; 253A>T; 262T>A.

[0042] In particular embodiment the coding sequence of the RNA of the invention is not the coding sequence of SARS-CoV-2 gRNA.

[0043] In specific embodiment of the RNA of the present invention, the RNA is a synthetic or recombinant RNA (not natural).

[0044] As used herein, the term “SARS-CoV-2” refers to severe acute respiratory syndrome coronavirus 2 known by the provisional name 2019 novel coronavirus (2019-nCoV) is the cause of the respiratory coronavirus disease 2019 (COVID-19). Taxonomically, it is a strain of the Severe acute respiratory syndrome-related coronavirus (SARS-CoV), a positive-sense singlestranded RNA virus. It is contagious in humans, and the World Health Organization (WHO) has designated the ongoing pandemic of CO VID-19 a Public Health Emergency of International Concern. SARS-CoV-2 virion is approximately 50-200 nanometres in diameter. Like other coronaviruses, SARS-CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins; the N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope. The spike protein, which has been imaged at the atomic level using cryogenic electron microscopy is the protein responsible for allowing the virus to attach to the membrane of a host cell.

[0045] In a specific embodiment, the isolated RNA molecule comprises or consists of the SARS-COV2 LEADER SEQUENCE of SEQ ID N°1 (called the leader conserved with first 75 nucleotides (nt.) at their 5 'end), but may have a variable sequence (O to 190 nt. long) (LS-XXX) as describe for 5’UTR sequence of (b2), to (b8) and in the Table 1.

[0046] Table 1

[0047] In bold the variable region sequence after the common conserved sequence of 75 nucleotide.

[0048] A ribonucleic acid (RNA) molecule as used in accordance with the present invention relates to a polymeric molecule which is assembled as a chain of the nucleotides termed G, A, U, and C. Each nucleotide in RNA contains a ribose sugar, with carbons numbered 1' through 5'. A nitrogenous base is attached to the 1' position, in general, adenine (A), cytosine (C), guanine (G), or uracil (U). In a polymeric RNA molecule, a phosphate group is attached to the 3' position of one ribose and the 5' position of the next. Thus, the nucleotides in a polymeric RNA molecule are covalently linked to each other wherein the phosphate group from one nucleotide binds to the 3' carbon on the subsequent nucleotide, thereby forming a phosphodiester bond. Accordingly, an RNA strand has a 5' end and a 3' end, so named for the carbons on the ribose ring. By convention, upstream and downstream relate to the 5' to 3' direction in which RNA transcription takes place. Preferably, the RNA molecule is a messenger RNA (mRNA) molecule. mRNA is a large family of RNA molecules that convey genetic information from DNA to the ribosome, where they specify the amino acid sequence of the protein products of gene expression. Following transcription of primary transcript mRNA (known as pre-mRNA) by RNA polymerase II, processed, mature mRNA is translated into a polymer of amino acids: a protein, as summarized in the central dogma of molecular biology. As in DNA, mRNA genetic information is in the sequence of nucleotides, which are arranged into codons consisting of three bases each. Each codon encodes for a specific amino acid, except the stop codons, which terminate protein synthesis.

[0049] RNA molecule of present invention comprises two main modules as defined in items (a) and (b), above. In addition, the RNA molecule of present invention preferably comprises a UTR at its 3' end. Thus, the RNA molecule of the present invention resembles with respect to its structure a "normal" mRNA molecule which occurs in nature, harboring a coding region as well as (5' and 3') untranslated regions (UTRs) and, optionally, a poly-A tail.

[0050] The term "coding region including a start codon at its 5' end" as used in accordance with the present invention relates to a sequence which is composed of codons, which are decoded and translated into protein by the ribosome in accordance with the information provided by the genetic code. Coding regions commonly begin with a start codon at their 5' end and end with a stop codon. In general, the start codon is an AUG triplet and the stop codon is UAA, UAG, or UGA. In addition to being protein- coding, portions of coding regions may serve as regulatory sequences in the pre- mRNA as exonic splicing enhancers or exonic splicing silencers. The coding region of a gene coding for a polypeptide or a protein as used in accordance with the present invention is also known as the coding sequence or CDS (from coding DNA sequence) and is that portion of a gene's DNA or RNA, composed of exons, that codes for a polypeptide or protein. The coding region in mRNA is flanked by the 5'- untranslated region (5' UTR) and the 3 '-untranslated region (3' UTR) which are also parts of the exons. Moreover, mRNA molecules may further comprise a so-called 5' cap and a poly-A tail. The 5' cap, the 5' UTR, the 3' UTR and the poly-A tail are regions of an mRNA molecule which are not translated into protein.

[0051] Most mRNAs are capped at their 5 ’ extremity and poly adenylated at their 3Zend in order to ensure integrity, stability and efficient translation of the mRNA. The cap structure consists of a 7-methylguanylate residue (such as m7-GpppG cap analog (New England Biolabs) connected to the mRNA via an unusual 5'to 5'triphosphate linkage [4], The cap interacts with the eIF4F complex, which is composed of the cap-binding protein eIF4E, the scaffold protein eIF4G and the RNA helicase eIF4A. The eIF4F complex plays a crucial role during initiation because it establishes a physical and functional link between the mRNA (through a cap-eIF4E interaction) and the 43 S complex (through an eIF4G-eIF3 interaction) [5-7], Once bound to the 5'end of the mRNA, the 43 S complex scans the 5'untranslated region (UTR) in a 5’ to 3’ direction to reach the cognate AUG start codon.

[0052] Accordingly the RNA molecule of the present invention may optionally contain at 5’ extremity (before the 5' UTR Sars-Cov2 leader sequence) as a cap structure an additional residue (nucleotide) selected from the list consisting of guanine or 7-methylguanylate residue.

[0053] In a particular embodiment the cap structure is 7-methylguanylate residue (such as m7- GpppG cap analog)

[0054] The term "untranslated region" or "UTR" as used in accordance with the present invention relates to sections of the mRNA upstream of the start codon and downstream of the stop codon that are not translated, and are, therefore, termed the five prime untranslated region (5' UTR) and three prime untranslated region (3' UTR), respectively. These regions are transcribed with the coding region and thus are exonic as they are present in the mature mRNA.

[0055] As used in the present invention, the 3' untranslated region (3 '-UTR) relates to the section of messenger RNA (mRNA) that immediately follows the translation termination codon. The 3' UTR may comprise regulatory regions within the 3'- untranslated region which are known to influence polyadenylation and stability of the mRNA. Many 3'-UTRs also contain AU-rich elements (AREs). Furthermore, the 3'- UTR may preferably contain the sequence AAUAAA that directs addition of several hundred adenine residues called the poly(A) tail to the end of the mRNA transcript.

[0056] As used in the present invention, the 5' untranslated region (5' UTR) (also known as a Leader Sequence or Leader RNA) is the region of an mRNA that is directly upstream of the start codon. The 5' UTR begins at the transcription start site and ends one nucleotide (nt) before the start codon (usually AUG) of the coding region. In eukaryotes the length of the 5' UTR is generally from 50 to several thousand nucleotides long but sometimes also shorter UTRs occur in eukaryotes.

[0057] An RNA molecule of the present invention may also contain a poly-A tail. A poly-A tail is a long sequence of adenine nucleotides (often several hundred) added to the 3' end of the pre-mRNA by a process called polyadenylation. This tail promotes export from the nucleus and translation, and protects the mRNA from degradation. Polyadenylation is the addition of a poly(A) tail to a messenger RNA. The poly(A) tail consists of multiple adenosine monophosphates; in other words, it is a stretch of RNA that has only adenine bases. In eukaryotes, polyadenylation is part of the process that produces mature messenger RNA (mRNA) for translation.

[0058] One module of the RNA molecule, i.e., "a coding region including a start codon at its 5' end coding for a polypeptide" (module (a)) is not particularly limited and may be any desired coding region which is to be expressed in a given cell. As regards the preferred embodiments of the term "a coding region including a start codon at its 5' end coding for a polypeptide" (module (a)) the same applies, mutatis mutandis, to the RNA molecule of the present invention as has been set forth above in the context of the DNA molecule of the present invention.

[0059] The RNA molecule of the present invention comprises a module (b) directly upstream of said coding sequence, wherein said module (b) is a 5 ’UTR comprising a SARS-COV2 LEADER SEQUENCE (called LS) of SEQ ID N°1 AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUG UAGAUCUGUUCUCUAAACGAAC (LS sequence of ORF7a / ORF8)

[0060] In a particular embodiment the RNA molecule of the present invention comprises a module (b) directly upstream of said coding sequence, wherein said module (b) is a 5 ’UTR selected from the group consisting of:

[0061] (bl ) an UTR of the sequence : LS (SEQ ID NO:1 ) (ORF7a-ORF8? )

[0062] (b2) an UTR of the sequence LS-A (SEQ ID NO:2) (ORF S)

[0063] (b3) an UTR of the sequence LS- AAACTAAA (AAACUAAA) (SEQ ID NO:3) (ORF N);

[0064] (b4) an UTR of the sequence LS

[0065] UUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGC UUCACACUCAAAAGAAAGACAGA (SEQ ID NO:4) (ORF 7B); (b5) an UTR of the sequence LS-

[0066] GCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUU UUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAU UCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAG (SEQ ID NO: 5) (ORF 6);

[0067] (b6) an UTR of the sequence :

[0068] LS-UAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCC

[0069] (SEQ ID NO:6) (ORF M); and

[0070] (b7) an UTR of the sequence LS- UU (SEQ ID NO:7) (ORF E and ORF 3A);

[0071] (b8) an UTR of the sequence LS-

[0072] UUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGU AUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCU UCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCU AGGUUUCGUCCGGGUGUGACCGAAAGGUAAG (SEQ ID NO: 8) (ORF 1AB); and or a sequence wherein in said UTR sequence the triplet AUG at position 107-109 of SEQ ID NO:8 is substituted by triplet different from AUG and / or at least one triplet UAA / UGA at position 136; 137-139; 251-253; and 262-264 of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA UGA or UAG (stop codon); and

[0073] (b9) an UTR sequence substantially homologous to the sequence of (bl) to (b8) preferably an sequence at least 80% identical to the sequence of (bl) to (b8).

[0074] In a particular embodiment the triplet AUG at position 107-109 of SEQ ID NO:8 is substituted by a triplet UAA or UUG or CCG.

[0075] In a particular embodiment at least one the triplet UAA / UGA at position 134-136; 137- 139; 251-253; and 262-264 of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA UGA or UAG (stop codon).

[0076] In a particular embodiment all the triplet UAA / UGA at position 134-136; 137-139; 251- 253; and 262-264 of SEQ ID NO:8 are deleted or substituted by a triplet different from UAA UGA or UAG (stop codon);.

[0077] In a particular embodiment nucleotides of SEQ ID NO:8 is mutated in at the following position : 136A>C; 137T>A; 139A>T; 140OA; 253A>T; 262T>A. The term "coding region including a start codon at its 5' end" as used in accordance with the present invention relates to a DNA sequence which is composed of codons, which are transcribed into an mRNA molecule by a DNA-dependent RNA-polymerase wherein a corresponding mRNA molecule may be decoded and translated into proteins by the ribosome in accordance with the information provided by the "genetic code". Coding regions commonly begin with a start codon at their 5' end and end with a stop codon. In general, the start codon is an ATG triplet (corresponding to an AUG triplet on the RNA level) and the stop codon is TAA, TAG or TGA (corresponding to UAA, UAG, or UGA on the RNA level). In addition to being protein-coding, portions of coding regions may seNe as regulatory sequences in the pre-mRNA as exonic splicing enhancers or exonic splicing silencers. The coding region of a gene coding for a polypeptide or a protein as used in accordance with the present invention is also known as the coding sequence or CDS (from coding DNA sequence) and is that portion of a gene's DNA or RNA, composed in most cases of exons, that codes for a polypeptide or protein. The coding region in mRNA is flanked by the 5'-untranslated region (5' UTR) and the 3 '-untranslated region (3' UTR) which are also parts of the exons. Moreover, mRNA molecules may further comprise a so-called 5' cap and a poly-A tail. The 5' cap, the 5' UTR, the 3' UTR and the poly-A tail are regions of an mRNA molecule which are not translated into protein.

[0078] As used in the present invention, the 3' untranslated region (3 '-UTR) relates to the section of messenger RNA (mRNA) that immediately follows the translation termination codon. The 3' UTR may comprise regulatory regions within the 3'- untranslated region which are known to influence polyadenylation and stability of the mRNA. Many 3'-UTRs also contain AU-rich elements (AREs). Furthermore, the 3'- UTR may preferably contain the sequence AAUAAA that directs addition of several hundred adenine residues called the poly(A) tail to the end of the mRNA transcript.

[0079] The 5' untranslated region (5' UTR) (also known as a Leader Sequence or Leader RNA) is the region of an mRNA that is directly upstream of the start codon. The 5' UTR begins at the transcription start site and ends one nucleotide (nt) before the start codon (usually AUG in the mRNA) of the coding region. In eukaryotes the length of the 5' UTR is generally from 50 to several thousand nucleotides long but sometimes also shorter UTRs occur in eukaryotes.

[0080] A RNA “substantially homologous” to a reference RNA may derive from the reference sequence by one or more substitutions. Two (ribo)nucleotide sequences are "substantially homologous" or "substantially similar" when one or more (ribo)nucleotide base are replaced by a biologically similar bases or when greater than 80 % of the (ribo)nucleotide bases are identical, or greater than about 90 %, preferably greater than about 95%, are similar (functionally identical). Preferably, the similar, identical or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program, or any of the programs known in the art (BLAST, FAST A, etc.). The percentage of identity may be calculated by performing a pairwise global alignment based on the Needleman-Wunsch alignment algorithm to find the optimum alignment (including gaps) of two sequences along their entire length, for instance using Needle, and using the BLOSUM62 matrix with a gap opening penalty of 10 and a gap extension penalty of 0.5.

[0081] According to the invention a first nucleic acid sequence having at least 80% of identity with a second nucleic acid sequence means that the first sequence has 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; or 99% of identity with the second nucleic acid sequence. Nucleic acid sequence identity is preferably determined using a suitable sequence alignment algorithm and default parameters, such as BLAST P (Karlin and Altschul, 1990).

[0082] The UTR sequence(s) having any of the above substitutions in comparison to a 5’UTR of the leader sequence LS (SEQ ID NO: 1) or in comparison to a UTR of the sequence LS with variable domain (SEQ ID NO:2 to SEQ ID N°8 ) may result in an RNA molecule showing the same or a similar, preferably a higher translation efficiency as an RNA molecule comprising a UTR of the leader sequence LS (SEQ ID NO:1) and an RNA molecule comprising a UTR of the sequence LS with variable domain (SEQ ID NO:2 to SEQ ID N°8 ), respectively. The translation efficiency of a given RNA molecule comprising a UTR as described herein can be determined by the skilled person by methods known in the art and as described in the following

[0083] The translation efficiency is the rate of mRNA translation into polypeptides or proteins within cells. The translation efficiency of a given mRNA is measured as the number of proteins or polypeptides which are translated or produced per mRNA per time unit. Translation is the process in which cellular ribosomes create proteins and is well-known to the skilled person. Briefly, in translation, messenger RNA (mRNA) which is produced by transcription from DNA is decoded by a ribosome to produce a specific amino acid chain or a polypeptide or a protein.

[0084] Thus, the translation efficiency of a given RNA molecule harbouring a modified UTR sequence with any of the above substitutions is preferably the same or higher in comparison to the translation efficiency of the same given RNA but harbouring an UTR of the leader sequence LS (SEQ ID NO: 1) or of the sequence LS with variable domain (SEQ ID NO:2 to SEQ ID N°8) as defined herein above, respectively. Accordingly, the number of proteins or polypeptides encoded by the coding region of the RNA molecule harbouring a modified UTR sequence with any of the above substitutions which are translated per RNA per time unit is at least the same or is, preferably, higher than the number of proteins or polypeptides encoded by the coding region of the RNA molecule harbouring an UTR of the leader sequence LS (SEQ ID NO: 1) or of the sequence LS with variable domain (SEQ ID NO:2 to SEQ ID N°8 ) as defined herein above, respectively, which are translated per RNA per time unit.

[0085] Translation efficiency, in the context of the present invention, is preferably the rate of mRNA translated into protein within a cell at a certain time point in relation to the amount of mRNA encoding the respective protein in said cell at the same time point. Thus, the translation efficiency is the quotient of the mRNA translated into protein within a cell at a certain time point and the amount of mRNA encoding the respective protein. Both parameters, i.e., the mRNA translated into a protein as well as the amount of mRNA encoding the respective protein, can be determined by methods known in the art. As non-limiting examples, the amount of mRNA translated into protein within a cell can, e g., be determined by as determined by measurement of the amount of protein produced by the given mRNA (by different methods such as flow cytometry (FC), radioisotope incorporation or enzymatic production) while the amount of mRNA encoding the respective protein can, e.g., be measured by qRT-PCR or northern blotting.

[0086] The UTR(s) as defined in item (b) herein-above is / are not particularly limited to the above specific sequences but may also relate to (a) UTR sequence(s) which comprise(s) a sequence which shows (a) nucleotide(s) addition(s) in comparison to such sequences, wherein the additional nucleotide(s) may be added at the 3' end and / or 5'-end of the above described UTR(s). The additional nucleotide(s) comprise polynucleotide chains of up to 0 (no changes),

[0087] I, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides, preferably of up to 20 nucleotides. More preferably,

[0088] I I, 12, 13, 14, 15, 16, 18, or 19 nucleotides are added at the3'end and / or 5'-end. Even more preferably of up to 30 nucleotides are added at the 3'end and / or 5'-end.

[0089] In light of the rationale that the addition of nucleotides is likely not to change the above functional properties of the respective UTR(s) the addition of the nucleotides may also have a length of up to 40, 50, 60, 70, 80, 90, or even 100 nucleotides or even more, up to 200, 300, 400 or 500 nucleotides as long as these sequences have a similar capability (in terms of the above-described translation efficiency) as the UTRs defined in item (b) herein-above.

[0090] One module of the RNA molecule, i.e., "a coding region including a start codon at its 5' end coding for a polypeptide" (module (a)) is not particularly limited and may be any desired coding region which is to be expressed in a given cell. Thus, this module may be a coding region coding for a desired polypeptide, i.e., the desired final product. The present invention is not limited with respect to the "coding region including a start codon at its 5' end coding for a polypeptide" since the nature of the coding region depends on the desired product which is to be produced in the cell. Such coding region can also be a nucleotide sequence which differs from a known natural sequence and contains mutations (i.e. point mutations, insertion mutation, deletions and combinations thereof). Moreover, such a coding region may partly or to the full extent be a codon optimized sequence derived from the natural sequence to be used as module (a). Codon optimization is a technique to maximize the protein expression by increasing the translational efficiency of the mRNA derived from a gene of interest. It is known that natural genes do not use the available codons randomly, but show a certain preference for particular codons for the same amino acid. Thus, because of the degeneracy of the genetic code - one amino acid can be encoded by several codons - transforming the nucleotide sequence of a gene of interest into a set of preferred codons of the same or another species.

[0091] As mentioned, module (a) is not particularly limited and may be any desired coding region which is to be expressed in a given cell. Thus, in the context of the present invention, "coding region" should be understood to mean any poly- ribonucleotide molecule which, if introduced into a cell, can be translatable to a polypeptide / protein or fragment thereof. The terms "polypeptide" and "protein" here encompass any kind of amino acid sequence, i.e., chains of two or more amino acids which are each linked via peptide bonds and also includes peptides and fusion proteins.

[0092] In a preferred embodiment, the "coding region including a start codon at its 5' end coding for a polypeptide" contains a ribonucleotide sequence which encodes a polypeptide / protein or fragment thereof whose function in the cell or in the vicinity of the cell is needed or beneficial, e.g., a protein the lack or defective form of which is a trigger for a disease or an illness, the provision of which can moderate or prevent a disease or an illness, or a protein which can promote a process which is beneficial for the body, in a cell or its vicinity. The coding region may contain the sequence for the complete protein or a functional variant thereof. Further, the ribonucleotide sequence of the coding region can encode a protein which acts as a factor, inducer, regulator, stimulator or enzyme, or a functional fragment thereof, where this protein is one whose function is necessary in order to remedy a disorder, in particular a metabolic disorder or in order to initiate processes in vivo such as the formation of new blood vessels, tissues, etc. Here, functional variant is understood to mean a fragment which in the cell can undertake the function of the protein whose function in the cell is needed or the lack or defective form whereof is pathogenic.

[0093] In a preferred embodiment, the "coding region including a start codon at its 5' end coding for a polypeptide" encodes a therapeutically or pharmaceutically active polypeptide or protein having a therapeutic or preventive effect. As such, the RNA molecule of the present invention comprising said "coding region including a start codon at its 5' end coding for a polypeptide" may be used in nucleic acid therapy and related applications. In this context, in accordance with the invention, the translation of a RNA molecule of the present invention into a polypeptide or a protein may be intended to compensate or complement endogenous gene expression, in particular in cases where an endogenous gene is defective or silent, leading to no, insufficient or a defective or a dysfunctional product of gene expression such as is the case with many metabolic and hereditary diseases like cystic fibrosis, haemophilia or muscular dystrophy to name a few. The translation of a RNA molecule of the present invention into a polypeptide or a protein may also be intended to have the product of the expression interact or interfere with any endogenous cellular process such as the regulation of gene expression, signal transduction and other cellular processes. The translation of a RNA molecule of the present invention into a polypeptide or a protein may also be intended to give rise to an immune response in context of the organism in which a transfected or transduced cell resides or is made to reside. Examples are the genetic modification of antigen-presenting cells such as dendritic cells in order to have them present an antigen for vaccination purposes. Another example is the translation of a RNA molecule of the present invention into a polypeptide or a protein wherein said coding region encodes cytokines. This may, e.g., be desirable in tumors in order to elicit a tumor-specific immune response. Furthermore, translation of a RNA molecule of the present invention into a polypeptide or a protein may also be intended to generate in vivo or ex vivo transiently genetically modified cells for cellular therapies such as modified T-cells or precursor or stem or other cells for regenerative medicine.

[0094] In other preferred embodiments, the "coding region including a start codon at its 5' end coding for a polypeptide" may encode a protein which plays a part in growth processes and angiogenesis, which are for example necessary in controlled regeneration and can then be formed specifically by introduction of the RNA molecule according to the invention. This can for example be useful in growth processes or for the treatment of bone defects, tissue defects and in the context of implantation and transplantation. As mentioned, the RNA molecule of the present invention comprising a "coding region including a start codon at its 5' end coding for a polypeptide" can appropriately be used in any case where a polypeptide or a protein, which would naturally be present in the body but is not present or is present in deficient form or in too small a quantity because of gene defects or diseases, is to be provided to the body. Proteins and the genes encoding them, the deficiency or defect whereof are linked with a disease, are known. The respective intact version of the coding region coding for the intact polypeptide or protein can be used in accordance with the present invention.

[0095] Numerous genetic disorders, caused by the mutation of a single gene are known and candidates for mRNA therapeutic approaches. Disorders caused by single-gene mutations, like cystic fibrosis, haemophilia and many others, can be dominant or recessive with respect to the likelihood that a certain trait will appear in the offspring. While a dominant allele manifests a phenotype in individuals who have only one copy of the allele, for a recessive allele the individual must have two copies, one from each parent to become manifest. In contrast, polygenic disorders are caused by two or more genes and the manifestation of the respective disease is often fluent and associated to environmental factors. Examples for polygenic disorders are hypertension, elevated cholesterol level, cancer, neurodegenerative disorders, mental illness and others. Also in these cases therapeutic mRNA representing one or more of these genes may be beneficial to those patients. Furthermore, a genetic disorder must not have been passed down from the parents' genes, but can also be caused by new mutations. Also in these cases therapeutic mRNA representing the correct gene sequence may be beneficial to the patients.

[0096] An online catalog with presently 22,993 entries of Human Genes and Genetic Disorders together with their respective genes and a description of their phenotypes are available at the ONIM (Online Mendelian Inheritance in Man) webpage (http: / / onim.org); sequences of each are available from the Uniprot database (http: / / www.uniprot.org).

[0097] Examples of genes in which a defect leads to a disease which can be treated with the RNA molecule of the present invention wherein the RNA molecule comprises a "coding region including a start codon at its 5' end coding for a polypeptide" which encodes an intact version of the protein or a functional fragment thereof of the above disclosed defective gene. In particular embodiments, hereditary diseases can be mentioned which for example affect the lungs, such as SPB (surfactant protein B) deficiency, ABCA3 deficiency, cystic fibrosis and al -antitrypsin deficiency, or which affect plasma proteins (e.g. congenital hemochromatosis (hepcidin deficiency), thrompotic thrombocytopenic purpura (TPP, AD AMTS 13 deficiency) and cause clotting defects (e g. haemophilia a and b) and complement defects (e.g. protein C deficiency), immune defects such as for example SCID (caused my mutations in different genes such as: RAG1, RAG2, JAK3, IL?R, CD45, CD3o, CD3£) or by deficiencies due to lack of adenosine desaminase for example (ADA-SCID), septic granulomatosis (e g. caused by mutations of the gp-91-phox gene, the p47-phox gene, the p67-phox gene or the p33-phox gene) and storage diseases like Gaucher's disease, Fabry's disease, Krabbe's disease, MPS I, MPS II (Hunter syndrome), MPS VI, Glycogen storage disease type II or muccopolysacchaidoses.

[0098] Other disorders for which the present invention comprising a "coding region including a start codon at its 5' end coding for a peptide" can be useful include disorders such as SMNl-related spinal muscular atrophy (SMA); amyotrophic lateral sclerosis (ALS);GALT- related galactosemia; Cystic Fibrosis (CF); SLC3Al-related disorders including cystinuria; COL4A5 -related disorders including Alport syndrome; galactocerebrosidase deficiencies; X- linked adrenoleukodystrophy and adrenomyeloneuropathy; Friedreich's ataxia; Pelizaeus- Merzbacher disease; TSC1 and TSC2-related tuberous sclerosis; Sanfilippo 8 syndrome (MPS 1118); CTNS- related cystinosis; the FMRI-related disorders which include Fragile X syndrome, Fragile X-Associated Tremor / Ataxia Syndrome and Fragile X Premature Ovarian Failure Syndrome; Prader-Willi syndrome; hereditary hemorrhagic telangiectasia (AT); Niemann-Pick disease Type Cl; the neuronal ceroid lipofuscinoses-related diseases including Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), Juvenile Batten disease, Santavuori-Haltia disease, Jansky-Bielschowsky disease, and PTT-1 and TPP1 deficiencies; EIF281, EIF282, EIF283, EIF284 and EIF285 -related childhood ataxia with central nervous system hypomyelination / vanishing white matter; CACNA1A and CACNB4-related Episodic Ataxia Type 2; the MECP2-related disorders including Classic Rett Syndrome, MECP2 -related Severe Neonatal Encephalopathy and PPM-X Syndrome; CDKLS-related Atypical Rett Syndrome; Kennedy's disease (SBMA); Notch-3 related cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); SCN1A and SCNIB-related seizure disorders; the Polymerase G-related disorders which include Alpers-Huttenlocher syndrome, POLG-related sensory ataxic neuropathy, dysarthria, and ophthalmoparesis, and autosomal dominant and recessive progressive external ophthalmoplegia with mitochondrial DNA deletions; X-Linked adrenal hypoplasia; X-linked agammaglobulinemia; Fabry disease; and Wilson's disease. In all these diseases, a protein, e g. an enzyme, is defective, which can be treated by treatment with the RNA molecule of the present invention, which makes the protein encoded by the defective gene or a functional fragment thereof available. Transcript replacement therapies / enzyme replacement therapies do not affect the underlying genetic defect, but increase the concentration of the enzyme in which the patient is deficient. As an example, in Pompe's disease, the transcript replacement therapy / enzyme replacement therapy replaces the deficient Lysosomal enzyme acid alpha-glucosidase (GAA).

[0099] Thus, non-limiting examples of proteins which can be encoded by the "coding region including a start codon at its 5' end coding for a polypeptide" of module (a) according to the invention are erythropoietin (EPO), growth hormone (somatotropin, hGH), cystic fibrosis transmembrane conductance regulator (CFTR), growth factors such as GM-SCF, G-CSF, MPS, protein C, hepcidin, ABCA3 and surfactant protein B. Further examples of diseases which can be treated with the RNA according to the invention are hemophilia A / B, Fabry's disease, CGD, ADAMTS13, Hurler's disease, X chromosome-mediated A-y-globulinemia, adenosine deaminase-related immunodeficiency and respiratory distress syndrome in the newborn, which is linked with SP-B. Particularly preferably, the "coding region including a start codon at its 5' end coding for a polypeptide" of the DNA molecule according to the invention contains the sequence for surfactant protein B (SP-B) or for erythropoietin. Further examples of proteins which can be encoded by the "coding region including a start codon at its 5' end coding for a polypeptide" of the DNA molecule according to the invention are growth factors such as human growth hormone hGH, BMP -2 or angiogenesis factors.

[0100] Alternatively the nucleic acids may encode full length antibodies or smaller antibodies (e g., both heavy and light chains) to confer immunity to a subject. In another embodiment, the "coding region including a start codon at its 5' end coding for a polypeptide" may encode a functional monoclonal or polyclonal antibody, which may be useful for targeting and / or inactivating a biological target (e.g., a stimulatory cytokine such as tumor necrosis factor). Similarly, the "coding region including a start codon at its 5' end coding for a polypeptide" may encode, for example, functional anti -nephrotic factor antibodies useful for the treatment of membranoproliferative glomerulonephritis type II or acute hemolytic uremic syndrome, or alternatively may encode anti-vascular endothelial growth factor (VEGF) antibodies useful for the treatment of VEGF -mediated diseases, such as cancer.

[0101] Module (a), i.e., the "coding region including a start codon at its 5' end coding for a polypeptide", may be a coding region encoding a polypeptide or a protein which can be used in genome editing technologies. Genome editing is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome of an organism using nucleases. These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired by non-homologous end-joining or homologous recombination, resulting in targeted mutations in the genome, thereby "editing" the genome. Numerous genome editing systems utilizing different polypeptides or proteins are known in the art, i.e., e.g., the CRISPR-Cas system, meganucleases, zinc finger nucleases (ZFNs) and transcription activator-like effector-based nucleases (TALEN). Methods for genome engineering are reviewed in Trends in Biotechnology, 2013, 31 (7), 397-405.

[0102] Thus, in a preferred embodiment, the "coding region including a start codon at its 5' end coding for a polypeptide" contains a desoxyribonucleotide sequence which encodes a polypeptide or protein of the Cas (CRISPR associated protein) protein family, preferably Cas9 (CRISPR associated protein 9). Proteins of the Cas protein family, preferably Cas9, may be used in CRISPR / Cas9 based methods and / or CRISPR / Cas9 genome editing technologies. CRISPR-Cas systems for genome editing, regulation and targeting are reviewed in Nat. Biotechnol., 2014, 32(4):347- 355.

[0103] In another preferred embodiment, the "coding region including a start codon at its 5' end coding for a polypeptide" contains a ribonucleotide sequence which encodes a meganuclease. Meganucleases are endodeoxyribonucleases which, in contrast to "conventional" endodeoxyribonucleases, recognize a large recognition site (e.g., a double-stranded DNA sequence of 12 to 40 base pairs). As a result, the respective site occurs only few times, preferably only once, in any given genome. Meganucleases are therefore considered to be the most specific naturally occurring restriction enzymes and, accordingly, are suitable tools in genome editing technologies.

[0104] In another preferred embodiment, the "coding region including a start codon at its 5' end coding for a polypeptide" contains a desoxyribonucleotide sequence which encodes a zinc finger nuclease (ZFN). ZFNs are artificial restriction enzymes generated by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. Zinc finger domains can be engineered to target specific desired DNA sequences and this enables zinc-finger nucleases to target unique sequences within complex genomes. By taking advantage of the endogenous DNA repair machinery, ZFNs can be used to precisely alter the genome of higher organisms and are, therefore, suitable tools in genome editing technologies. In another preferred embodiment, the "coding region including a start codon at its 5' end coding for a polypeptide" contains a desoxyribonucleotide sequence which encodes a transcription activator-like effector nuclease (TALEN). TALENs are restriction enzymes that can be engineered to cut specific sequences of DNA. TALENs are fusion proteins wherein a TAL effector DNA-binding domain is fused to a DNA cleavage domain of a nuclease. Transcription activator-like effectors (TALEs) can be engineered to bind practically any desired DNA sequence. Thus, when combined with a nuclease, DNA can be cut at specific desired locations.

[0105] The RNA molecules of the present invention containing the above-described UTR(s) may be generated / synthesized recombinantly (e.g., in an in vivo or an in vitro system) or synthetically by methods known to the person skilled in the art.

[0106] In vitro transcription of RNA usually requires a linear DNA template containing a double-stranded promoter region where the DNA-dependent RNA-polymerase binds and initiates RNA synthesis while the coding region may be double-stranded or single-stranded. In case the linear DNA template contains a single-stranded coding region, the antisense strand (i.e., the strand which is read by the DNA-dependent polymerase) of the coding region is part of the template. Common DNA-dependent RNA-polymerases are the T7 polymerase, the T3 polymerase, SP6 polymerase and the KI 1 polymerase..

[0107] Transcription templates for an in vitro transcription include, for example, cDNA templates synthesized from an RNA precursor, templates generated by PCR, chemically synthesized oligonucleotides and plasmid constructs Many widely used plasmid cloning vectors harbour phage polymerase promoters located on each side of the multiple cloning site to allow transcription of either strand of a nucleotide sequence inserted into the multiple cloning site. Commonly used cloning vectors include for example Invitrogen's pCRII, Promega's pGEM and Stratagene's pBluescript vectors. Ambion's pTRIPLEscript family of vectors contain all three phage polymerase promoters in tandem (on the same side of the multiple cloning site), allowing any of the three polymerases, SP6, T7 or T3 to be used.

[0108] The RNA molecules of the present invention may be produced recombinantly in in vivo systems by methods known to the person skilled in the art.

[0109] Alternatively, the RNA molecules of the present invention may be produced in an in vitro system using, for example, an in vitro transcription system. In vitro transcription systems are commonly known and usually require a purified linear DNA template containing a DNA sequence "encoding" the RNA molecule wherein said DNA sequence is under the control of an appropriate promoter. Moreover, an in vitro transcription system also commonly requires ribonucleoside triphosphates, a buffer system that includes OTT and magnesium ions, and an appropriate RNA polymerase which provides the enzymatic activity for the in vitro transcription of the DNA sequence into a corresponding RNA molecule of the present invention.

[0110] Furthermore, the RNA molecules may be chemically synthesized, e.g., by conventional chemical synthesis on an automated nucleotide sequence synthesizer using a solid-phase support and standard techniques or by chemical synthesis of the respective DNA-sequences and subsequent in vitro or in vivo transcription of the same.

[0111] In accordance with the above, the present invention provides RNA molecules / polyribonucleic acid molecules, preferably modified polyribonucleic acid molecules, wherein one module of said RNA molecule, i.e., "a coding region including a start codon at its 5' end" (module (a)), encodes for a polypeptide. The terms nucleic acid and polynucleotide are used interchangeably and include any compound and / or substance that comprises a polymer of nucleotides. The term nucleotide includes deoxynucleotides and ribonucleotides. The terms ribonucleic acid and polyribonucleotide are used interchangeably and, in certain embodiments, include any compound and / or substance that comprises a polymer of nucleotides wherein greater than 50% of the nucleotides are ribonucleotides. In certain embodiments, polyribonucleotides comprise a polymer of nucleotides wherein greater than 60%, 70%, 75%, 80%, 90%, greater than 95%, greater than 99% or 100% of the nucleotides are ribonucleotides. Polyribonucleotides wherein one or more nucleotides are modified nucleotides may be referred to as modified polyribonucleotides However, the term polyribonucleotides may include modified polyribonucleotides.

[0112] The sequence of the RNA molecules / polyribonucleotides can be derived from, for example, any suitable nucleic acid that comprises the genetic information of a gene of interest. Examples of nucleic acids include genomic DNA, RNA, or cDNA from any bacterial or archaeal cell comprising the gene(s) of interest. The polynucleotides can be derived from nucleic acids carrying mutated genes and polymorphisms. An RNA molecule / polyribonucleotide of the present invention comprises a sequence which is not particularly limited and may comprise, as module A, any desired coding region which is expressed in a given cell. In a preferred embodiment, said sequence may be a coding region coding for a desired polypeptide / protein as outlined above. Preferably, in line with the above, the RNA molecule / polyribonucleotide further comprises an untranslated sequence positioned upstream (51) of the module A's start codon, an untranslated sequence positioned downstream (3') of module A's stop codon, or both an untranslated sequence positioned upstream (5') of module A's start codon and an untranslated sequence positioned downstream (3') of module A's stop codon. In a preferred embodiment, an RNA molecule / polyribonucleotide of the present invention may be a modified RNA molecule / polyribonucleotide.

[0113] In addition to the four classical ribonucleotides, namely, adenosine, guanosine, cytidine and uridine, there exist numerous analogs of each of these nucleobases. Sometimes throughout and in the literature, these analogs, or RNA molecules / polyribonucleotides that include one or more of these analogs, are referred to as modified (e.g., modified nucleotides or modified ribonucleotides). Some analogs differ from the above canonical nucleobases, but yet can exist in nature. Other analogs are non-naturally occurring. Either type of analog is contemplated.

[0114] In certain embodiments, RNA molecules / polyribonucleotides of the present invention comprise nucleotide analogs (e.g., the polyribonucleotide comprises a modified polyribonucleotide). Exemplary nucleotide analogs are provided below (e.g., analogs of U; analogs of C; analogs of A; analogs of G). In addition, in certain embodiments, an RNA molecule / polyribonucleotide or other nucleic acid of the disclosure may also comprise (in addition to or alternatively) modifications in the phosphodiester backbone or in the linkage between nucleobases. Exemplary nucleic acids that can form part or all of an RNA molecule / polyribonucleotide of the disclosure include, but are not limited to, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a beta -o-ribo configuration, alpha - LNA having an alpha -L-ribo configuration (a diastereomer of LNA), 2'-amino-LNA having a 2 -amino functionalization, and 2'-amino-alpha-LNA having a 2 -amino functionalization) or hybrids thereof.

[0115] In certain embodiments, a modification may be on one or more nucleoside(s) or the backbone of the nucleic acid / polynucleotide molecule. In certain embodiments, a modification may be on both a nucleoside and a backbone linkage. In certain embodiments, a modification may be engineered into a polynucleotide in vitro. In certain embodiments, a modified ribonucleotide / nucleotide may also be synthesized post-transcriptionally by covalent modification of the classical / natural ribonucleotides / nucleotides.

[0116] An RNA molecule / polyribonucleotide of the present invention can be a modified RNA molecule / polyribonucleotide and, in certain embodiments, can comprise analogs of purines and / or analogs of pyrimidines. In certain embodiments, a modified RNA molecule / polyribonucleotide of the present invention comprises a pyrimidine analog, such as an analog of uridine and / or an analog of cytidine. In certain embodiments, a modified RNA molecule / polyribonucleotide of the present invention comprises an analog of uridine and an analog of cytidine. In certain embodiments, the modified RNA molecule / polyribonucleotide does not comprise analogs of adenosine and / or analogs of guanosine. In certain embodiments, the RNA molecule / polyribonucleotide comprises a single type of analog of uridine and a single type of analog of cytidine (e.g., one type of analog, not a single molecule of analog - the single analog may be present at any of several percentages described herein). In other embodiments, the RNA molecule / polyribonucleotide comprises more than one type of analog of uridinevand / or cytidine and, optionally and if present, one or more analogs of adenosine and / or guanosine (or none of either or both).

[0117] In some cases a modified uridine (e.g., analog of uridine) is selected from 2- thiouridine, 5' -methyluridine, pseudouridine, 5-iodouridine (15U), 4-thiouridine (S4U), 5 -bromouridine (Br5U), 2, -methyl-2, -deoxyuridine (U2'm), 2, -amino-2, -deoxyuridine (U2'NH2), 2'-azido-2'- deoxyuridine (U2'N3), and 2'-fluoro-2'-deoxyuridine (U2'F). In some cases, a modified cytidine (e g., analog of cytidine) is selected from 5- methylcytidine, 3 -methylcytidine, 2-thio-cytidine, 2, -methyl-2, -deoxycytidine (C2,m), 2'-amino-2'-deoxycytidine (C2'NH2), 2'-fluoro-2'- deoxycytidine (C2'F), 5- iodocytidine (15C), 5-bromocytidine (Br5C) and 2'-azido-2'- deoxy cytidine (C2'N3). Note that when referring to analogs, the foregoing also refers to analogs in their 5' triphosphate form. In certain embodiments, the cytidine analog is 5-iodocytidine and the uridine analog is 5-iodouridine.

[0118] In some embodiments, the RNA molecule / polyribonucleotide is a modified RNA molecule / polyribonucleotide. In some cases, the modified RNA molecule / polyribonucleotide is at least 25% more stable as compared to a non- modified (or unmodified) RNA molecule / polyribonucleotide. In some cases, the modified RNA molecule / polyribonucleotide can be at least 30% more stable, at least 35% more stable, at least 40% more stable, at least 45% more stable, at least 50% more stable, at least 55% more stable, at least 60% more stable, at least 65% more stable, at least 70% more stable, at least 75% more stable, at least 80% more stable, at least 85% more stable, at least 90% more stable, or at least 95% more stable as compared to a non-modified RNA molecule / polyribonucleotide. In certain embodiments, stability is measured in vivo. In certain embodiments, stability is measured in vitro. In certain embodiments, stability is quantified by measuring the half-life of the polyribonucleotide.

[0119] A RNA molecule / polyribonucleotide of the present invention can have nucleotides that have been modified in the same form or else a mixture of different modified nucleotides. The modified nucleotides can have modifications that are naturally or not naturally occurring in messenger RNA. A mixture of various modified nucleotides can be used. For example one or more modified nucleotides within an RNA molecule / polyribonucleotide can have natural modifications, while another part has modifications that are not naturally found in mRNA. Additionally, some modified nucleotides can have a base modification, while other modified nucleotides have a sugar modification. In the same way, it is possible that all modifications are base modifications or all modifications are sugar modifications or any suitable mixture thereof. In some cases, the stability of the modified RNA molecule / polyribonucleotide can be selectively optimized by changing the nature of modified bases within the modified poly ribonucl eoti de .

[0120] In certain embodiments, an analog (e g., a modified nucleotide) can be selected from the group comprising pyridin-4-one ribonucleoside, 5-iodouridine, 5 -iodocytidine, 5- aza-uridine, 2'-amino-2'-deoxycytidine, 2'-fluor-2'-deoxycytidine, 2-thio-5-aza-uridine, 2-thiouridine, 4- thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3- methyluridine, 5- carboxymethyl- uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl- pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl- pseudouridine, 5-taurinomethyl-2- thio-uridine, l-taurinomethyl-4-thio-uridine, 5- methyl-uridine, 1-methyl-pseudouridine, 4- thio-I-methyl-pseudouridine, 2-thio-I- methyl-pseudouridine, 1-methyl-I-deaza-pseudouridine,

[0121] 2-thio-l-methyl-l-deaza- pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio- dihydrouridine, 2-thio- dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4- methoxy- pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine, pseudoisocytidine,

[0122] 3- methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, 5-methylcytidine, N4- methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo- cytidine, pyrrolo- pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio- pseudoisocytidine, 4-thio-

[0123] 1-methyl-pseudoisocytidine, 4-thio-l-m ethyl- 1 -deaza- pseudoisocytidine, 1-methyl-I-deaza- pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine,

[0124] 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy- pseudoisocytidine, 4-methoxy-I-methyl- pseudoisocytidine, 2-aminopurine, 2, 6- diaminopurine, 7-deaza-adenine, 7-deaza-8- aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8- aza-2-aminopurine, 7-deaza-2,6- diaminopurine, 7-deaza-8-aza-2,6- diaminopurine, 1- methyladenosine, N6- methyladenosine, N6-isopentenyladenosine, N6-(cis- hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine,

[0125] N6- glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6- threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2- methylthioadenine, 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza- guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio- 7-deaza-guanosine, 6-thio-7- deaza-8-aza-g uanosine, 7-methyl-guanosine, 6-thio-7- methyl-guanosine, 7-methylinosine, 6- m ethoxy-guanosine, 1 -methylguanosine, N2- methylguanosine, N2,N2-dimethyl guanosine, 8- oxo-guanosine, 7-methyl-8-oxo- guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio- guanosine, and N2,N2- dimethyl-6-thio-guanosine.

[0126] In molecular biology and genetics, upstream and downstream both refer to a relative position in an RNA molecule. In the context of the present invention, upstream is toward the 5' end of the RNA molecule and downstream is toward the 3' end of the molecule.

[0127] Accordingly, in the present invention, the UTR defined in item (b), above, is located directly upstream of the coding region of item (a), more specifically, directly upstream of the start codon of the coding region. Thus, "directly upstream" in this context means that there is / are no further nucleotides between the UTR defined in item (b) and the coding sequence which initiates with a start codon. Thus, the coding region which initiates with a start codon is immediately adjacent to said UTR sequence.

[0128] The RNA molecule may be present in the form of fused RNA sequences of modules

[0129] (a) and (b) (defined in items (a) and (b), respectively, above) i.e., a (fusion) RNA molecule which is formed by the expression of a hybrid gene made by combining at least two nucleotide sequences encoding said modules. Typically, as will be explained in more detail further below, this can be accomplished by cloning a cDNA into an expression vector which allows for the transcription into the RNA molecule. Accordingly, the DNA molecule encoding the RNA molecule of the present invention may be a fused DNA sequence, i.e., a chimeric molecule which is formed by j oining two or more polynucleotides via the phosphate group from one nucleotide bound to the 3' carbon on another nucleotide, forming a phosphodiester bond between the respective ends of one module and the end of another molecule. In this way, the above DNA molecules encoding said at least two modules are joined together in the form of a DNA molecule. Such a recombinant DNA molecule is then transcribed into its corresponding RNA nucleic acid sequence.

[0130] As mentioned above, the RNA molecule of the present invention may also harbour a poly-A tail. As used herein, a poly-A tail relates to a sequence of adenine nucleotides located at the 3' end of the RNA. A poly-A tail is commonly added to the 3' end of the RNA by a process called poly adenylation. Thus, the present invention relates to any of the above-described RNA, wherein the RNA molecule comprises a poly-A tail at the 3' end.

[0131] The length of the poly-A tail is not particularly limited. Yet, in preferred embodiments, the RNA molecule of the present invention comprises a poly-A tail at the 3' end wherein the poly-A tail has a length of at least 50, 60, 70, 80, 90, 100 or 110 nucleotides. In a more preferred embodiment, the RNA molecule of the present invention comprises a poly-A tail at the 3' end wherein the poly-A tail has a length of at least 120 nucleotides. In other preferred embodiments, the RNA molecule of the present invention comprises a poly-A tail at the 3' end wherein the poly-A tail has a length of at least 150, 200, 250, 300, 350, 400, 500, 600, 700, 800, 900 or 1000 nucleotides.

[0132] In case the RNA molecule of the present invention is produced by an in vitro transcription method as described herein further below the poly-A tail is located at the 3' end of the RNA adjacent to the UTR at the 3' end of the RNA molecule while the plasmid harbouring the RNA molecule of the present invention is linearized prior to the in vitro transcription downstream of the poly-A tail in order to assure that the in vitro transcribed RNA molecule contains said poly-A tail.

[0133] As mentioned above, the RNA molecule of the present invention may be present in the form of fused RNA sequences of modules (a) and (b }, i.e., a (fusion) RNA molecule which is formed by the transcription of a hybrid gene made by combining at least two nucleotide sequences encoding said modules. Typically, this is accomplished by cloning a cDNA into an expression vector which allows for the transcription of the entire RNA molecule A variety of methods are known for making fusion constructs, including nucleic acid synthesis, hybridization and / or amplification to produce a synthetic double-stranded nucleic acid molecule "encoding" the RNA molecule of the present invention. Such a double-stranded nucleic acid molecule (i.e., DNA molecule) harbours on one strand (i.e., on the coding or sense strand) the DNA sequence corresponding to the RNA molecule of the present invention and, accordingly, "encodes" the RNA molecule of the present invention. In other words, such a double-stranded nucleic acid / DNA molecule comprises on a strand the genetic information which corresponds to the transcribed RNA molecule of the present invention as defined herein above. The term "coding" or "encoding" in the context of the present invention is not only used in its conventional sense, i.e., to relate to a gene's DNA that codes for a protein (and, accordingly, the genetic information which may be translated into a polypeptide or a protein amino acid sequence). Rather, in terms of the present invention, in a construct wherein the individual DNA sequences encoding the modules (a) and (b) are "fused" or linked into a single (chimeric) DNA molecule, the construct also comprises a component (i.e., module (b)) which is not translated into a protein. Nevertheless, the DNA sequence corresponding to module (b) provides the information, i.e., the "code", for the 5' UTRs' structure and, accordingly, the term "encoding" in the present invention also relates to the genetic information for the UTRs which may be expressed, i.e., transcribed, if, e.g., present in a double-stranded nucleic acid molecule. Thus, the term "encoding" in the context of the present invention, although it is commonly only used to relate to the coding / expression of a protein, is to be understood in a way that the nucleic acid molecule can be transcribed into the corresponding RNA molecule which harbours parts encoding a protein or a polypeptide (i.e., module (a)) and parts "encoding" the UTR (i.e., module (b)) wherein the latter represent the final product when expressed since UTRs are not translated into proteins or polypeptides. Such a double-stranded nucleic acid may be inserted into expression vectors by standard molecular biology techniques (see, e.g. Sambrook et al., Molecular Cloning, A laboratory manual, 2nd Ed, 1989). The term "vector" such as "expression vector" or "cloning vector" in the sense of the present invention is understood as a circular, double-stranded unit of DNA that replicates within a cell independently of the chromosomal DNA and which is used as a vehicle to carry genetic material into a cell, where it can be replicated and / or expressed (i.e., transcribed into RNA and translated into a amino acid sequence). A vector containing foreign DNA is termed recombinant DNA. The vector itself is generally a DNA sequence that typically consists of an insert (i.e., module (b) which is not translated into a protein and module (a) the coding region) and a larger sequence that serves as the "backbone" of the vector. Plasmids in the sense of the present invention are most often found in bacteria and are used in recombinant DNA research to transfer genes between cells and are as such a subpopulation of "vectors" as used in the sense of the present invention.

[0134] • Nucleic Acid encoding the RNA molecule (vectors and host cells)

[0135] Thus, the present invention also relates to a nucleic acid molecule encoding the RNA molecule of the present invention.

[0136] The nucleic acid is, for example a DNA, encoding the two main modules (i.e., module (a) and module (b)) of the RNA molecule of the present invention. The above nucleic acid molecule of the present invention preferably is a recombinant nucleic acid molecule. The nucleic acid molecule of the invention may be synthetic or semi- synthetic.

[0137] It is evident to the person skilled in the art that further regulatory sequences may be added to the nucleic acid molecule of the invention encoding the RNA molecule. For example, transcriptional enhancers and / or sequences which allow for induced expression may be employed. A suitable inducible system is for example tetracycline- regulated gene expression as described, e.g., by Gossen and Bujard, Proc. Natl. Acad. Sci. USA 89 (1992), 5547-5551) and Gossen, Trends Biotech. 12 (1994), 58- 62, or a dexamethasone-inducible gene expression system as described, e.g. by Crook, EMBO J. 8 (1989), 513-519.

[0138] The present invention also relates to a vector, preferably an expression vector, comprising the nucleic acid molecule of the present invention.

[0139] The vector of the present invention may be, e.g., a plasmid, cosmid, virus, bacteriophage or another vector used e g. conventionally in genetic engineering, and may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions.

[0140] The nucleic acid molecule of the present invention and vectors of the invention may be designed for direct introduction or for introduction via liposomes, viral vectors (e.g. adenoviral, retroviral), electroporation, ballistic (e.g. gene gun) or other delivery systems into the cell. Additionally, a baculoviral system can be used as eukaryotic expression system for the nucleic acid molecules of the invention.

[0141] The present invention also relates to a host cell comprising the vector of the present invention. Thus, the present invention relates to a host transfected or transformed with the vector of the invention or a non-human host carrying the vector of the present invention, i.e. to a host cell or host which is genetically modified with a nucleic acid molecule of the present invention or with a vector comprising such a nucleic acid molecule. The term "genetically modified" means that the host cell or host comprises in addition to its natural genome a nucleic acid molecule or vector according to the invention which was introduced into the cell or host or into one of its predecessors / parents. The nucleic acid molecule or vector may be present in the genetically modified host cell or host either as an independent molecule outside the genome, preferably as a molecule which is capable of replication, or it may be stably integrated into the genome of the host cell or host. The transformation of the host cell with a vector according to the invention can be carried out by standard methods, as for instance described in Sambrook and Russell (2001), Molecular Cloning: A Laboratory Manual, CSH Press, Cold Spring Harbor, NY, USA; Methods in Yeast Genetics, A Laboratory Course Manual, Cold Spring Harbor Laboratory Press, 1990. The host cell is cultured in nutrient media meeting the requirements of the particular host cell used, in particular in respect of the pH value, temperature, salt concentration, aeration, antibiotics, vitamins, trace elements etc. The host cell of the present invention may be any prokaryotic or eukaryotic cell. Suitable prokaryotic cells are those generally used for cloning like E. coli or Bacillus subtilis. Furthermore, eukaryotic cells comprise, for example, fungal or animal cells. Examples for suitable fungal cells are yeast cells, preferably those of the genus Saccharomyces and most preferably those of the species Saccharomyces cerevisiae. Suitable animal cells are, for instance, insect cells, vertebrate cells, preferably mammalian cells, such as e.g. HEK293, NSO, CHO, COS-7, MOCK, U2- OSHela, NIH3T3, MOLT-4, Jurkat, PC-12, PC-3, IMR, NT2N, Sk- n-sh, CaSki, C33A.

[0142] Further suitable cell lines known in the art are obtainable from cell line depositories, like, e.g., the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) or the American Type Culture Collection (ATCC). In accordance with the present invention, it is furthermore envisaged that primary cells / cell cultures may function as host cells. Said cells are in particular derived from insects (like insects of the species Drosophila or Blatta) or mammals (like human, swine, mouse or rat). Said host cells may also comprise cells from and / or derived from cell lines like neuroblastoma cell lines. The above mentioned primary cells are well known in the art and comprise, inter alia, primary astrocytes, (mixed) spinal cultures or hippocampal cultures.

[0143] The present invention also relates to a composition comprising the nucleic acid molecule of the present invention, the vector of the present invention or the host cell of the present invention.

[0144] • Method of producing RNA molecules

[0145] The present invention also relates to methods of producing the RNA molecule of the present invention by culturing a host cell harbouring an expression vector encoding the individual modules of the present invention or the entire RNA molecule of the invention in culture medium, and recovering the RNA molecule from the host cell or culture medium. The present invention may also relate to a method for producing an RNA molecule of the present invention comprising the cultivation of the host cell of the present invention and optionally recovering the RNA molecule from the culture.

[0146] Methods of recovering and / or subsequently purifying the RNA molecule of the present invention are known to the person skilled in the art.

[0147] The present invention also relates to methods of producing in an in vitro reaction the RNA molecule of the present invention by methods known to the person skilled in the art. More specifically, the RNA molecule of the present invention may be produced in vitro using an in vitro transcription system. In vitro transcription systems are commonly known and usually require a purified linear DNA template containing a DNA sequence "encoding" module (b) and module (a) as outlined above wherein said DNA sequence is under the control of an appropriate promoter. Moreover, an in vitro transcription system also commonly requires ribonucleotide triphosphates, a buffer system that includes OTT and magnesium ions, and an appropriate RNA polymerase which provides the enzymatic activity for the in vitro transcription of the DNA sequence into the RNA molecule of the present invention.

[0148] Methods which are commonly used to produce RNA molecules using in vitro transcription are well-known to the person skilled in the art and are, e.g., described in Methods Mol. Biol. 703 (2011):29-41.

[0149] As mentioned above, in case the RNA molecule of the present invention is produced by an in vitro transcription method as described herein further below the above poly- A tail may be part of the RNA molecule of the present invention (and not necessarily originally located on the cloning vector) and is located at the 3' end of the RNA, e.g. adjacent to the UTR at the 3' end of the RNA molecule. In case the RNA molecule of the present invention is produced by an in vitro transcription method the plasmid harboring the RNA molecule of the present invention is linearized prior to the in vitro transcription downstream of the poly-A tail in order to assure that the in vitro transcribed RNA molecule contains said poly-A tail.

[0150] Alternatively, the RNA molecule of the present invention may also be chemically synthesized, e.g., by conventional chemical synthesis on an automated nucleotide sequence synthesizer using a solid-phase support and standard techniques.

[0151] The present invention also relates to methods of producing in an in vitro reaction the RNA molecule of the present invention by methods known to the person skilled in the art and as outlined above and recovering the RNA molecule from the reaction.

[0152] Methods of recovering and / or subsequently purifying the RNA molecule of the present invention are known to the person skilled in the art.

[0153] Use of an RNA molecule of the present invention and pharmaceutical or vaccinal composition

[0154] The RNA molecule of the present invention can readily be used in in vitro translation systems known in the art for the efficient expression of any desired polypeptide or protein encoded by the coding region of module (a).

[0155] In vitro translation systems are known in the art and can directly be used with the RNA molecule of the present invention. Alternatively, these in vitro translation systems can be combined with the above in vitro transcription systems. Corresponding cell-free systems for the in vitro transcription and / or in vitro translation are known and available. These cell-free systems for the protein synthesis (also called in-vitro protein synthesis or abbreviated CFPS), allow for the expression / production of a polypeptide or a protein using biological machinery without the use of living cells. In these systems, the in vitro protein synthesis environment is not constrained by a cell wall or homeostasis conditions necessary to maintain cell viability and enables direct access and control of the translation environment which is advantageous for a number of applications including optimization of protein production, optimization of protein complexes, to study protein synthesis, incorporating non-natural amino acids, high-throughput screens, and synthetic biology. Common components of a cell free reaction include a cell extract, an energy source, a supply of amino acids, cofactors such as magnesium, and the DNA or RNA encoding the desired polypeptide or protein. A cell extract may be obtained by lysing the cell of interest and centrifuging out the cell walls, DNA genome, and other debris. The remains are the necessary cell machinery including ribosomes, aminoacyl-tRNA synthetases, translation initiation and elongation factors, etc. In a cell-free system for the synthesis of polypeptides or proteins starting from DNA (i.e., in a system including a step of in vitro transcription and in vitro translation), two types of DNA are commonly used, i.e., either plasmids or linear expression templates (LETs). In a cell-free system for the synthesis of polypeptides or proteins starting from RNA (i.e., in a system including a step of in vitro translation only) an RNA may directly be used. These in vitro cell-free reactions require an energy source which is usually provided by a separate mixture containing the needed energy source, along with a supply of amino acids which are added to the extract for the reaction. Common energy sources are phosphoenol pyruvate, acetyl phosphate, and creatine phosphate. Common cell extracts which are commonly used are made from Escherichia coli (ECE), rabbit reticulocytes (RRL), wheat germ (WGE), and insect cells (ICE). All of these extracts are commercially available.

[0156] Accordingly, the present invention also relates to the use of an RNA molecule of the present invention for the in vitro translation of a desired polypeptide or protein encoded by a coding region contained in said RNA molecule.

[0157] • Pharmaceutical composition

[0158] The RNA molecules as defined above are particularly useful in medical settings and in the treatment of a certain disease and, in particular, in RNA-based therapies. Thus, the present invention also relates to a pharmaceutical composition comprising the RNA molecule of the present invention, the nucleic acid molecule of the present invention, the vector of the present invention or the host cell of the present invention and optionally a pharmaceutically acceptable carrier.

[0159] The term "treatment" and the like are used herein to generally mean obtaining a desired pharmacological and / or physiological effect. Accordingly, the treatment of the present invention may relate to the treatment of (acute) states of a certain disease but may also relate to the prophylactic treatment in terms of completely or partially preventing a disease or symptom thereof. Preferably, the term "treatment" is to be understood as being therapeutic in terms of partially or completely curing a disease and / or adverse effect and / or symptoms attributed to the disease. "Acute" in this respect means that the subject shows symptoms of the disease. In other words, the subject to be treated is in actual need of a treatment and the term "acute treatment" in the context of the present invention relates to the measures taken to actually treat the disease after the onset of the disease or the breakout of the disease. The treatment may also be prophylactic or preventive treatment, i.e., measures taken for disease prevention, e.g., in order to prevent the infection and / or the onset of the disease.

[0160] Accordingly, the present invention relates to a pharmaceutical composition comprising the RNA molecule according to the invention and a pharmaceutically acceptable carrier

[0161] The pharmaceutical composition of the present invention may be administered via a large range of classes of forms of administration known to the skilled person. Administration may be systemically, locally, orally, through aerosols including but not limited to tablets, needle injection, the use of inhalators, creams, foams, gels, lotions and ointments.

[0162] As mentioned, the present invention relates to a pharmaceutical composition, comprising an effective amount of the RNA molecule (or the nucleic acid molecule, the vector or the host cell) of the present invention in accordance with the above and at least one pharmaceutically acceptable excipient or carrier.

[0163] An excipient or carrier is an inactive substance formulated alongside the active ingredient, i.e., the RNA molecule (or the nucleic acid molecule, the vector or the host cell) of the present invention for the purpose of bulking-up formulations that contain potent active ingredients. Excipients are often referred to as "bulking agents," "fillers," or "diluents". Bulking up allows convenient and accurate dispensation of a drug substance when producing a dosage form. They also can serve various therapeutic- enhancing purposes, such as facilitating drug absorption or solubility, or other pharmacokinetic considerations. Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance concerned such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation over the expected shelf life. The selection of appropriate excipients also depends upon the route of administration and the dosage form, as well as the active ingredient and other factors.

[0164] Thus, the pharmaceutical composition comprising an effective amount of the RNA molecule (or the nucleic acid molecule, the vector or the host cell) of the present invention may be in solid, liquid or gaseous form and may be, inter alia, in a form of

[0165] (a) powder(s), (a) tablet(s), (a) solution(s) or (an) aerosol(s). It is preferred that said pharmaceutical composition optionally comprises a pharmaceutically acceptable carrier and / or diluent.

[0166] Examples of suitable pharmaceutical carriers, excipients and / or diluents are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil / water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well-known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose, i.e., in "an effective amount" which can easily be determined by the skilled person by methods known in the art. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's or subject's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.

[0167] Thus, preferably, the RNA molecule (or the nucleic acid molecule, the vector or the host cell) of the present invention is included in an effective amount. The term "effective amount" refers to an amount sufficient to induce a detectable therapeutic response in the subj ect to which the pharmaceutical composition is to be administered. In accordance with the above, the content of the RNA molecule (or the nucleic acid molecule, the vector or the host cell) of the present invention in the pharmaceutical composition is not limited as far as it is useful for treatment as described above, but preferably contains 0.0000001-10% by weight per total composition. Further, the RNA molecule (or the nucleic acid molecule, the vector or the host cell) described herein is preferably employed in a carrier. Generally, an appropriate amount of a pharmaceutically acceptable salt is used in the carrier to render the composition isotonic. Examples of the carrier include but are not limited to saline, Ringer's solution and dextrose solution. Preferably, acceptable excipients, carriers, or stabilisers are non-toxic at the dosages and concentrations employed, including buffers such as citrate, phosphate, and other organic acids; salt-forming counter-ions, e.g. sodium and potassium; low molecular weight {> 10 amino acid residues) polypeptides; proteins, e.g. serum albumin, or gelatine; hydrophilic polymers, e.g. polyvinylpyrrolidone; amino acids such as histidine, glutamine, lysine, asparagine, arginine, or glycine; carbohydrates including glucose, mannose, or dextrins; monosaccharides; di saccharides; other sugars, e.g. sucrose, mannitol, trehalose or sorbitol; chelating agents, e g. EDTA; non-ionic surfactants, e.g. Tween, Pluronics or polyethylene glycol; antioxidants including methionine, ascorbic acid and tocopherol; and / or preservatives, e.g. octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens, e.g. methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol). Suitable carriers and their formulations are described in greater detail in Remington's Pharmaceutical Sciences, 17th ed., 1985, Mack Publishing Co.

[0168] Therapeutic progress can be monitored by periodic assessment. The RNA molecule (or the nucleic acid molecule, the vector or the host cell) of the present invention or the pharmaceutical composition of the invention may be in sterile aqueous or non- aqueous solutions, suspensions, and emulsions as well as creams and suppositories. Examples of nonaqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like Furthermore, the pharmaceutical composition of the invention may comprise further agents depending on the intended use of the pharmaceutical composition. Said agents may be, e.g., polyoxyethylene sorbitan monolaurate, available on the market with the commercial name Tween, propylene glycol, EDTA, Citrate, Sucrose as well as other agents being suitable for the intended use of the pharmaceutical composition that are well- known to the person skilled in the art.

[0169] In accordance with this invention, the term "pharmaceutical composition" relates to a composition for administration to a patient, preferably a human patient.

[0170] The pharmaceutical composition of the present invention may be for use in RNA- based therapies. As mentioned above, the RNA molecule of the present invention comprising a "coding region coding for a polypeptide" can be used in RNA-based therapies wherein the "coding region coding for a polypeptide" encodes a therapeutically or pharmaceutically active polypeptide or protein having a therapeutic or preventive effect. Thus, in preferred embodiments, the pharmaceutical composition of the present invention may be for use in RNA- based therapies in the treatment or prevention of a disease as recited in the above section regarding the therapeutical protein or polypeptide. Accordingly, RNA-based therapies in accordance with the present invention may be for use in the treatment or prevention of a disease as recited above.

[0171] Thus, the pharmaceutical composition of the present invention may be for use in RNA- based therapies in cases where the gene defects described above 1 lead to a disease which can then be treated or prevented by a transcript replacement therapy / enzyme replacement therapy with the RNA molecule of the present invention, wherein the RNA molecule comprises a "coding region for a polypeptide" which encodes an intact version of the protein or a functional fragment thereof compensating the disclosed defective gene. In particularly preferred embodiments, the pharmaceutical composition of the present invention may be for use in RNA- based therapies in the treatment or prevention of lysosomal diseases like Gaucher disease, Fabry disease, MPS I, MPS II (Hunter syndrome), MPS VI and Glycogen storage diseases such as for example Glycogen storage disease type I (von Gierecke's disease), type II (Pompe's disease), type Ill (Cori's disease, type IV (Andersen's disease, type V (McArdle's disease, type VI (Hers disease), type VII (Tauri's disease), type VII, type IX, type X, type XI (Fanconi -Bickel syndrome), type XI, or type 0. Transcript replacement therapies / enzyme replacement therapies beneficially do not affect the underlying genetic defect, but increase the concentration of the enzyme in which the patient is deficient. As an example, in Pompe's disease, the transcript replacement therapy / enzyme replacement therapy replaces the deficient Lysosomal enzyme acid alpha-glucosidase (GAA).

[0172] In other preferred embodiments, RNA-based therapies in accordance with the present invention may be for use in treating cancer, a cardiovascular disease, a viral infection, an immune dysfunction, an autoimmune disease, a neurologic disorder, an inherited metabolic disorders or a genetic disorder or any disease where a protein or protein fragment produced in a cell may have a beneficial effect for the patent. Examples of cancer include head and neck cancer, breast cancer, renal cancer, bladder cancer, lung cancer, prostate cancer, bone cancer, brain cancer, cervical cancer, anal cancer, colon cancer, colorectal cancer, appendix cancer, eye cancer, gastric cancer, leukemia, lymphoma, liver cancer, skin cancer, ovarian cancer, penile cancer, pancreatic cancer, testicular cancer, thyroid cancer, vaginal cancer, vulvar cancer, endometrial cancer, cardiac cancer and sarcoma. Examples of cardiovascular diseases include atherosclerosis, coronary heart disease, pulmonary heart disease and cardiomyopathy.

[0173] Examples of immune dysfunctions and autoimmune diseases include, but are not limited to, rheumatic diseases, multiple sclerosis and asthma.

[0174] Examples of viral infections include, but are not limited to, infections with human immunodeficiency virus, herpes simplex virus, human papillomavirus, coronavirus as well as hepatitis B and C virus.

[0175] Examples of neurologic disorders include, but are not limited to, Parkinson's disease, multiple sclerosis, and dementia.

[0176] Examples of inherited metabolic disorders include, but are not limited to, Gaucher's disease and Phenylketonuria.

[0177] The invention also relates to a method of an RNA-based therapy. Thus, the present invention relates to a method for the treatment of a disease such as cancer, a cardiovascular disease, a viral infection, an immune dysfunction, an autoimmune disease, a neurologic disorder, an inherited metabolic disorders or a genetic disorder by an RNA-based therapy. As regards the preferred embodiments of the method for treatment the same applies, mutatis mutandis, as has been set forth above in the context of the RNA molecule or the pharmaceutical composition for use in RNA- based therapy as defined above. hi the present invention, the subject is, in a preferred embodiment, a mammal such as a dog, cat, pig, cow, sheep, horse, rodent, e.g., rat, mouse, and guinea pig, or a primate, e.g., gorilla, chimpanzee, and human. In a most preferable embodiment, the subject is a human

[0178] As mentioned above, the RNA molecules as defined above are particularly useful in medical settings and in the treatment of a certain disease and, in particular, in RNA- based therapies. Thus, the present invention also relates to a pharmaceutical composition comprising the RNA molecule, the nucleic acid molecule, the vector or the host cell of the present invention and optionally a pharmaceutically acceptable carrier.

[0179] Yet, in RNA therapies, it is often desirable to silence the effect of the RNA molecule at some stage.

[0180] This can, e.g., be done by making use of an RNAi (RNA interference) mechanism by using the nucleic acid strand which is complementary to the UTR sequence of the present invention. Accordingly, the complementary strand of such a UTR sequence may beneficially be used in medical settings after the treatment of the above diseases or after the above RNA- based therapies using the pharmaceutical composition of the present invention, thereby silencing the therapeutic RNA molecules of the present invention.

[0181] Thus, an RNAi-approach is also envisaged in context of this invention for use in the preparation of a pharmaceutical composition for silencing the effect of the therapeutic RNA molecules of the present invention.

[0182] The term "RNA interference" or "inhibiting RNA" (RNAi / iRNA) describes the use of double-stranded RNA to target specific mRNAs for degradation, thereby silencing their expression. Preferred inhibiting RNA molecules may be selected from the group consisting of double-stranded RNA (dsRNA), RNAi, siRNA, shRNA and stRNA. dsRNA matching a gene sequence is synthesized in vitro and introduced into a cell. The dsRNA may also be introduced into a cell in form of a vector expressing a target gene sequence in sense and antisense orientation, for example in form of a hairpin mRNA. The sense and antisense sequences may also be expressed from separate vectors, whereby the individual antisense and sense molecules form double-stranded RNA upon their expression. It is known in the art that in some occasions the expression of a sequence in sense orientation or even of a promoter sequence suffices to give rise to dsRNA and subsequently to siRNA due to internal amplification mechanisms in a cell. Accordingly, all means and methods which result in a decrease in activity of the polypeptide or protein encoded by the coding region are to be used in accordance with the present invention. For example sense constructs, antisense constructs, hairpin constructs, sense and antisense molecules and combinations thereof can be used to generate / introduce these siRNAs The dsRNA feeds into a natural, but only partially understood process including the highly conserved nuclease dicer which cleaves dsRNA precursor molecules into short interfering RNAs (siRNAs). The generation and preparation of siRNA(s) as well as the method for inhibiting the expression of a target gene is, inter alia, described in WO 02 / 055693, Wei (2000) Dev. Biol. 15:239-255; La Count (2000) Biochem. Paras. 111 :67-76; Baker (2000) Curr. Biol. 10: 1071-1074; Svoboda (2000) Development 127:4147-4156 or Marie (2000) Curr. Biol. 10:289-292. These siRNAs built then the sequence specific part of an RNA-induced silencing complex (RISC), a multicomplex nuclease that destroys messenger RNAs homologous to the silencing trigger). Elbashir (2001) EMBO J. 20:6877-6888 showed that duplexes of 21 nucleotide RNAs may be used in cell culture to interfere with gene expression in mammalian cells. It is already known that RNAi is mediated very efficiently by siRNA in mammalian cells but the generation of stable cell lines or non-human transgenic animals was limited. However, new generations of vectors may be employed in order to stably express, e.g. short hairpin RNAs (shRNAs). Stable expression of siRNAs in Mammalian Cells is inter alia shown in Brummelkamp (2002) Science 296:550-553. Also Paul (2002) Nat. Biotechnol. 20:505-508 documented the effective expression of small interfering RNA in human cells. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells was also shown by Yu (2002) PNAS 99:6047-6052. The shRNA approach for gene silencing is well known in the art and may comprise the use of st (small temporal) RNAs; see, inter alia, Paddison (2002) Genes Dev. 16:948-958. These approaches may be vector-based, e.g. the pSUPER vector, or RNA pollll vectors may be employed as illustrated, inter alia, in Yu (2002), loc. cit. ; Miyagishi (2002), loc. cit. or Brummelkamp (2002), loc. cit. It is envisaged that the regulatory sequences of the present invention are used in similar fashion as the systems based on pSUPER or RNA pollll vectors.

[0183] Methods to deduce and construct siRNAs are known in the art and are described in Elbashir (2002) Methods 26: 199-213, at the internet web sites of commercial vendors of siRNA, e.g. Qiagen GmbH (https: / / wwwl.qiagen.com / GeneGlobe / Default.aspx);Dharmacon (www.dharmacon.com); Xeragon Inc. (http: / / www.dharmacon.com / Default.aspx), and Ambion (www.ambion.com), or at the web site of the research group of Tom Tuschl (http: / / www.rockefeller.edu / labheads / tuschl / sima.html). In addition, programs are available online to deduce siRNAs from a given mRNA sequence (e g. http: / / www.ambion.com / techlib / misc / siRNA_fmder.html or http: / / katahdin.cshl.org:9331 / RNAi / html / mai.html). Uridine residues in the 2-nt 3' overhang can be replaced by 2'deoxythymidine without loss of activity, which significantly reduces costs of RNA synthesis and may also enhance resistance of siRNA duplexes when applied to mammalian cells (Elbashir (2001) loc. cit). The siRNAs may also be sythesized enzymatically using T7 or other RNA polymerases (Donze (2002) Nucleic Acids Res 30:e46). Short RNA duplexes that mediate effective RNA interference (esiRNA) may also be produced by hydrolysis with Escherichia coli RNase Ill (Yang (2002) PNAS 99:9942-9947). Furthermore, expression vectors have been developed to express double stranded siRNAs connected by small hairpin RNA loops in eukaryotic cells (e.g. (Brummelkamp (2002) Science 296:550-553). All of these constructs may be developed with the help of the programs named above. In addition, commercially available sequence prediction tools incorporated in sequence analysis programs or sold separately, e.g. the siRNA Design Tool offered by www.oligoEngine.com (Seattle, WA) may be used for siRNA sequence prediction. Accordingly, specific interfering RNAs can be used in accordance with the present invention as antagonists / silencers of the expression and / or function of the polypeptide or protein encoded by the coding region of the RNA molecule of the present invention. These siRNAs are formed by a complementary / antisense and a sense strand, whereby the antisense / sense strand preferably comprises at least 10, more preferably at least 12, more preferably at least 14, more preferably at least 16, more preferably at least 18, more preferably at least 19, 20, 21 or 22 nucleotides. In an even more preferred embodiment, the antisense / sense strand preferably comprises 25 or more nucleotides.

[0184] As mentioned above, methods for preparing siRNAs to be used in accordance with the present invention are well known in the art. Based on the teaching provided herein, a skilled person in the art is easily in the position not only to prepare such siRNAs but also to assess whether a siRNA is capable of antagonizing / inhibiting / silencing the polypeptide or protein encoded by the coding region of the RNA molecule of the present invention. It is envisaged herein that the above described siRNAs lead to a degradation of the RNA molecule of the present invention harbouring a coding region encoding a polypeptide or protein and an UTR module, and thus to a decreased polypeptide / protein level of the polypeptide or protein encoded by the coding region of the RNA molecule of the present invention

[0185] • Vaccine composition

[0186] Another object of the invention is a vaccine composition comprising an RNA molecule of the invention and / or the nucleic acid molecule of the invention and optionally an immunoadjuvant compound.

[0187] By “vaccine composition” it is herein intended a substance which is able to induce an immune response in an individual, and for example to induce the production of antibodies directed against a polypeptide produced by the RNA molecule of the invention and / or the nucleic acid molecule according to the invention.

[0188] A vaccine is defined herein as a biological agent which is capable of providing a protective response in an animal to which the vaccine has been delivered and is incapable of causing severe disease. The vaccine stimulates antibody production or cellular immunity against the pathogen causing the disease; administration of the vaccine thus results in immunity from the disease.

[0189] Preferably, said immunoadjuvant compound is selected in the group consisting of Freund complete adjuvant, Freund incomplete adjuvant, aluminium hydroxide, and calcium phosphate. The term “vaccine” is considered a prophylactic or therapeutic substance that typically provides at least one antigen, preferably an antigenic peptide or protein. “Provides at least one antigen” means that, for example, the vaccine includes an antigen or that the vaccine includes, for example, a molecule encoding the antigen. Thus, the vaccine of the present invention may be derived from, for example, a tumor antigen, bacterial, viral, fungal or protozoan antigen, autoantigen, allergen, or allogeneic antigen, and is preferably particularly envisaged to include at least one synthetic nucleic acid (RNA molecule of the invention or the nucleic acid molecule of to the invention) molecule encoding at least one antigenic (poly-)peptide or protein as defined herein, which induces an immune response against each antigen, when expressed in and presented to the immune system. However, synthetic nucleic acid (RNA) molecules encoding non-antigenic (poly-)peptides or proteins of interest may also be used in the vaccine of the present invention.

[0190] In the present invention, the synthetic nucleic acid molecule may be complexed with one or more lipids to form lipid nanoparticles or liposomes.

[0191] The synthetic nucleic acid (RNA) molecule in the present invention is complexed or associated with, i.e., one or more (poly-)cationic compounds, preferably (poly-)cationic polymers, (poly-)cationic peptides or proteins, for example protamine, (poly-)cationic polysaccharide and / or (poly-)cationic lipid. In this context, the term “complexed” or “associated” means a combination of at least one synthetic nucleic acid (RNA) molecule with the at least one compound that is intrinsically stable as a larger complex or assembly without a covalent bond with the same.

[0192] Lipid

[0193] In some embodiment, the synthetic nucleic acid (RNA) molecules of the present invention are complexed or associated with lipids (especially cationic and / or neutral lipids) to form one or more lipid nanoparticles or liposomes. Thus, in some embodiments, the synthetic nucleic acid (RNA) molecules of the present invention may be provided in the form of lipid- based formulations, in particular in the form of liposomes and / or lipid nanoparticles including the synthetic nucleic acid (RNA) molecules.

[0194] Lipid nanoparticles

[0195] In some preferred embodiments, synthetic nucleic acid (RNA) molecules of the present invention are complexed or associated with lipids (especially cationic and / or neutral lipids) to form one or more lipid nanoparticles. Preferably, the lipid nanoparticles (LNP) may include the following components: (a) at least one synthetic nucleic acid molecule (RNA) of the present invention; (b) a cationic lipid; (c) an aggregation reducing agent (e.g., for example polyethylene glycol (PEG) lipid or PEG- modified lipid); (d) optionally a non-cationic lipid (e.g., neutral lipid); and (e) optionally, sterol.

[0196] In some embodiments, the LNP may include, in addition to at least one synthetic nucleic acid molecule (RNA) of the present invention, (i) at least one cationic lipid, (ii) a neutral lipid, and (iii) sterol such as cholesterol, and PEG-lipid, wherein the cationic lipid is present in an amount of about 20 to 60%, the neutral lipid is present in an amount of 5 to 25%, the sterol is present in an amount of 25 to 55% and the PEG-lipid is present in an amount of 0.5 to 15%.

[0197] In some embodiments, the synthetic nucleic acid molecule (RNA) of the present invention may be formulated into aminoalcohol lipidoid. The aminoalcohol lipidoid that may be used in the present invention may be prepared by the method described in U.S. Patent No. 8,450,298, which is incorporated herein by reference in its entirety.

[0198] Liposome

[0199] In some embodiments, the synthetic nucleic acid (RNA) molecules of the present invention are formulated into liposomes. The cationic lipid-based liposomes may form complexes with negatively charged nucleic acids (e.g., RNA) through electrostatic interactions, resulting in formation of complexes that offer possibilities of biocompatibility, low toxicity, and mass productivity required for in vivo clinical applications. Liposomes may be fused with the plasma membrane for absorption; first, the liposomes are processed through the phagocytosis pathway inside the cells and the nucleic acid is then released into the cytoplasm from the endosome / carrier. Liposomes have long been recognized as drug delivery vehicles due to excellent biocompatibility in that liposomes are basically analogs of biological membranes and may be prepared from both natural and synthetic phospholipids.

[0200] Liposomes are typically formed of a lipid bilayer, which may contain cationic, anionic or neutral (phospho)lipids and cholesterol, surrounding an aqueous core. Both the lipid bilayer and the aqueous core may contain hydrophobic or hydrophilic compounds. Liposomes may have one or more lipid membranes. Liposomes may be a single layer, called “unilamellar liposome”, or multiple layers, called “multilamellar liposomes”.

[0201] Liposome properties and behaviors in vivo may be modified by coating with a hydrophilic polymer, such as, by adding polyethylene glycol (PEG) to the liposome surface to provide steric stability. In addition, liposomes may be used for specific targeting by adhering ligands (e.g., antibodies, peptides and carbohydrates) to the surface thereof or to the end of the adhered PEG chain.

[0202] Liposomes typically exist as spherical vesicles and can range in size from 20 nm to several microns. Liposomes may have different diameters such as multilamellar vesicles (MLV), which may be several hundred nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, small unicellular vesicles (SUV) smaller than 50 nm in diameter, and large unilamellar vesicles (LUVs), which may be between 50 and 500 nm in diameter, but are not limited thereto. Liposome designs may include, but are not limited to, opsonins or ligands to improve adhesion of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis. Liposomes may have a low or high pH to enhance delivery of the pharmaceutical formulation.

[0203] In the present invention, the vaccine composition may further include one or more adjuvants or active agents.

[0204] In the broadest sense, the term “adjuvant” or “adjuvant component” is typically a pharmacological and / or immunological agent capable of modifying, e.g., enhancing, the effectiveness of another active agent, e.g., a therapeutic agent or vaccine. In this context, an “adjuvant” may be considered as any compound suitable to assist in the administration and delivery of the vaccine composition of the present invention. Specifically, the adjuvant preferably enhances the immune-stimulating property of the added vaccine. In addition, the adjuvant is not bound thereto and initiates or increases the immune response of the innate immune system, i.e., a non-specific immune response.

[0205] The “adjuvant” typically does not induce an adaptive immune response. To date, the “adjuvant” is not qualified as an antigen. That is, when administered, the vaccine of the invention typically initiates an adaptive immune response due to the antigenic peptide or protein encoded by at least one coding sequence of the synthetic nucleic acid (RNA) molecule contained in the vaccine.

[0206] Suitable adjuvants are known to those skilled in the art and may be selected from any adjuvant suitable in the present case, i.e., assisting in the induction of an immune response in a mammal, and may include: TDM, MDP, muramyl dipeptide, Pluronic, alum solution, aluminum hydroxide, ADJUMERTM (polyphosphazene); aluminum phosphate gel; glucans from algae; algamulin; aluminum hydroxide gel (alum); high protein-adsorption aluminum hydroxide gel; low-viscosity aluminum hydroxide gel; AF or SPT (emulsion of squalane (5%), Tween 80 (0.2%), Pluronic L121 (1.25%), phosphate-buffered saline, pH 7.4); or AVRIDINE™ (propanediamine), but is not limited thereto.

[0207] In another aspect, the present invention is directed to the use of the vaccine composition for the prevention of a disease.

[0208] As used herein, the term “disease” refers to an abnormality occurring from tumor antigens, bacteria, viruses, fungal or protozoan antigens, autoantigens, allergens, or allogeneic antigens, and may be cancer, tumor, an autoimmune disease, an inflammatory disease, a viral infection, a bacterial infection, a fungal infection, a protozoan infection, or the like, but is not limited thereto.

[0209] As used herein, the term “prevention” means any action that suppresses a disease or delays the progression thereof by administration of the vaccine composition of the present invention.

[0210] In another aspect, the present invention is directed to a method for preventing a disease including administering the vaccine composition.

[0211] In another aspect, the present invention is directed to the use of the vaccine composition for the preparation of drugs for preventing a disease.

[0212] The invention further relates to an in vitro or ex vivo method for translating a coding region of RNA molecule into a polypeptide or a protein encoded by said coding region using an 5’UTR as defined above.

[0213] In particular embodiment the 5’UTR sequence is selected from the group comprising or consisting of:

[0214] (bl ) an UTR of the sequence : LS (SEQ ID NO: 1 ) (ORF7a-ORF8 )

[0215] (b2) an UTR of the sequence : LS-A (SEQ ID NO:2) (ORF S)

[0216] (b3) an UTR of the sequence : LS- AAACUAAA (SEQ ID NO:3) (ORF N);

[0217] (b4) an UTR of the sequence LS

[0218] UUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACACUUUGC UUCACACUCAAAAGAAAGACAGA (SEQ ID NO:4) (ORF 7B);

[0219] (b5) an UTR of the sequence LS-

[0220] GCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACUCAGGUU UUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUAAACACAGACCAU UCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAG (SEQ ID NO: 5) (ORF 6); (b6) an UTR of the sequence : LS-UAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCC (SEQ ID NO:6) (ORF M); and

[0221] (b7) an UTR of the sequence LS-UU (SEQ ID NO:7) ((ORF E and ORF 3A);

[0222] (b8) an UTR of the sequence LS-

[0223] UUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGU AUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCU UCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCU AGGUUUCGUCCGGGUGUGACCGAAAGGUAAG ((SEQ ID NO: 8) ((ORF 1AB); and or a sequence wherein in said UTR sequence the triplet AUG at position 107-109 of SEQ ID NO:8 is substituted by a triplet different from AUG and / or at least one triplet UAA / UGA at position 134-136; 137-139; 251-253; and 262-264 of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA, UAG, UGA (stop codon) and

[0224] (b9) an UTR sequence substantially homologous to the sequence of (bl) to (b8) preferably an sequence at least 80% identical to the sequence of (bl) to (b8).

[0225] In a particular embodiment the triplet AUG at position 107-109 of SEQ ID NO:8 is substituted by a triplet UAA or UUG or CCG.

[0226] In a particular embodiment at least one the triplet UAA / UGA at position 134-136; 137- 139; 251-253; and 262-264 of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA UGA or UAG (stop codon).

[0227] In a particular embodiment all the triplet UAA / UGA at position 134-136; 137-139; 251- 253; and 262-264 of SEQ ID NO:8 are deleted or substituted by a triplet different from UAA UGA or UAG (stop codon).

[0228] In a particular embodiment nucleotides of SEQ ID NO:8 is mutated in at the following position : 136A>C; 137T>A; 139A>T; 140OA; 253A>T; 262T>A..

[0229] In particular embodiment the coding sequence of the RNA of the invention is not the coding sequence of SARS-CoV-2 gRNA.

[0230] In specific embodiment of the RNA of the present inventio, the RNA is a synthetic or recombinant RNA (not natural). FIGURES:

[0231] Figure 1.. Scheme of the SARS-CoV-2 gRNA and sgRNAs. The cap and poly(A) tail structures are indicated. The 5'UTR of each viral mRNA is underlined and is composed of the common leader sequence and the variable region. The other different box correspond to the different ORFs as indicated on the top.

[0232] Figure 2.. Modelization of the structure of the SARS-CoV-2 gRNA 5' UTR. This model, adapted from Miao et al. (2021)

[0073] , shows the different stem-loop (SL) RNA structures. Position of the AUG codons of uORF and main ORF are highlighted in black, and the TRS-L (surrounded nucleotides ).

[0233] Figure 3. Translation efficiency of the SARS-CoV-2 5 ’ UTRs. (A) The sequences corresponding to each 5'UTR have been cloned upstream of the Renilla ORF. (B and C) RRL and (D) untreated RRL have been programmed with capped and polyadenylated mRNAs harboring specifically the 5'UTR of the ORFlab, ORF-S, ORF-3a, ORF-E, ORF-M, ORF-6, ORF-7a, ORF-7b, ORF-8 or ORF-N. The resulting protein products have been resolved on (B) an SDS-PAGE and quantified with a phosphoImager, or (C and D) analyzed by luciferase assay. (E) Jurkat cells were electroporated with capped and polyadenylated mRNAs as indicated. After 90 min of incubation, the cellular extracts were used for RT-qPCR and luciferase assay. All the results are normalized to the globin 5'UTR expression (set at 100%). Values are the mean (+ / - S.D.) for three independent experiments (panels B and C) or (+ / - S.E.M.) for four independent experiments (panels D and E).

[0234] Figure 4. Divergence in translation efficiency between the 5'UTRs of MERS-CoV and SARS-CoV gRNA. (A) Percentage of identity between the 5'UTRs of MERS-CoV, SARS-CoV-1 and SARS-CoV-2 gRNAs resulting from a MUSCLE alignment (data not shown). (B) Scheme of capped and polyadenylated mRNAs coding for the Renilla reporter gene with the leader or the 5ZUTRORFlab from SARS-CoV-1 / 2 and MERS-CoV. (C) RRL was programmed with the corresponding in vitro transcribed reporter mRNAs. Expression products were quantified by luciferase assays and normalized to globin 5'UTR expression (set at 100%). (D) Jurkat cells were electroporated with capped and polyadenylated mRNAs as indicated. After 90 min of incubation, the cellular extracts were used for luciferase assay and RT-qPCR. All the results are normalized to the globin 5'UTR expression (set at 100%). Values shown are the mean (+ / - S.E.M.) for 6 (C) and 5 (D) independent experiments.

[0235] Figure 5. The effects of the cap and poly(A) tail on viral translation. Capped / polyadenylated (+ / +), capped / non-polyadenylated (+ / -), uncapped / polyadenylated (- / +) or uncapped / non-polyadenylated (- / -) Globin Renilla, 5'pj'pj^ORFiab j<enj||a ancf leader Renilla RNAs were translated in (A) the RRL or in (B) the untreated RRL. Translational products were analyzed by luciferase assays and normalized to the (- / -) condition (arbitrary set at 1). Values shown are the mean + / - S.D. for three independent experiments.

[0236] Figure 6. Requirement for the eIF4F complex. (A) Schematic cartoon of the eIF4F complex, which is composed of eIF4E, eIF4G and eIF4A. The interactions with the PIC, cap analog, L protease and hippuristanol are depicted on the figure. (B) RRL was treated with cap analog (1 pM) or with water (ctrl) and then programmed with capped and poly adenylated globin-Renilla and SARS-CoV-2 leader or 5 ' UTR0RFlab-Renilla mRNAs. Products of expression were quantified by luciferase assays and normalized to the control condition (set at 100%). (C, D, E and F) Untreated RRL was pre-incubated alone (ctrl) or in presence of different amounts of L protease (pL) as indicated, and then programmed with (D) globin-Renilla, (E) EMCV IRES-Renilla, (F) SARS-CoV-2 leader or 5'UTR0RFlab-Renilla mRNAs. Translation products were (C) resolved by a 7.5% SDS-PAGE and then transferred to a PVDF membrane for Western blotting analysis against eIF4G, or (D, E and F) analyzed by luciferase assay and normalized to the control condition (set at 100%). (G) RRL pre-treated with DMSO or increasing amounts (pM) of hippuristanol (hipp.) was programmed for 30 min with globin- Renilla, HCV-IRES Renilla, SARS-CoV-2 leader or ORF-lab 5ZUTR-Renilla mRNAs. Expression products were analyzed by luciferase assay and normalized to the control condition (set at 100%). Values shown are the mean (+ / - S.D.) for three independent experiments.

[0237] Figure 7. The 5'UTR uORF differentially regulates translation from SARS-CoV-2 and MERS-CoV. (A) Scheme of the reporter mRNA with the 5'UTRORF lab of SARS-CoV- 2 or MERS-CoV gRNA with their respective uORF and positions. (B) Capped and polyadenylated mRNA harboring the SARS-CoV-2 5'UTR gRNA WT or the Mut-AUG107 or uORF -phase mutations were translated in the RRL. Translation products were resolved by 12% SDS-PAGE and quantified with a phosphoImager. (C) Capped and polyadenylated mRNA harboring the MERS-CoV 5'UTR gRNA WT or the Mut-AUG158 mutation, were translated in the RRL. Translation products were resolved by 12% SDS-PAGE and quantified with a phosphoImager. (D) Jurkat cells were electroporated with capped and polyadenylated mRNAs as indicated. After 90 min of incubation, the cellular extracts were used for luciferase assay and RT-qPCR. Values shown are the mean (+ / - S.D.) for three independent experiments.

[0238] Figure 8. Translation efficiency of the SARS-CoV-2 O1AB and mRNA vaccines 5'UTRs. The sequences corresponding to each 5'UTR have been cloned upstream of the Renilla ORF. Rabbit reticulocyte lysate (RRL) have been programmed with capped and polyadenylated mRNAs containing the 5'UTR of SARS-CoV-2 ORF lab, Pfizer-BioNTech BNT162b2 mRNA vaccine, or Moderna mRNA-1273 vaccine. The resulting protein products were analyzed using a luciferase assay. All results were normalized to the expression of the globin 5'UTR (set at 1).

[0239] Figure 9. The uORF within the SARS-CoV-2 5* UTR regulates translation efficiency. Capped and polyadenylated mRNA harboring the SARS-CoV-2 5' UTR wild type (WT) gRNA, the Mut-AUG107, or the globin 5' UTR upstream renilla reporter gene were translated in the RRL. The AUG codon was mutated in either a UUG or a CCG codon. The resulting protein products were analyzed using a luciferase assay. All results were normalized to the expression of the globin 5' UTR (set at 1)

[0240] EXAMPLE 1 :

[0241] Materials and Methods

[0242] 2.1. DNA Constructs

[0243] The pGlo-Renilla, pEMCV-Renilla, pHCV-Renilla and pMMl-L-protease constructs have been previously described [87-89], The leader sequence and the 5 UTR (5 UTR0RFlab) of SARS-CoV-1 (NC_004718.3), MERS-CoV (NC_038294) and SARS-CoV-2 (NC_045512.2) gRNA have been generated by consecutive PCRs with specific primers (data not shown). The resulting PCR products were digested with the BamHI restriction enzyme and inserted into the pRenilla vector between the Bglll and BamHI restriction sites. The 5'UTRs of each SARS- CoV-2 sgRNA associated to the coding region of the Renilla luciferase were produced by consecutive PCRs with specific primers (data not shown), digested with BamHI and EcoRV restrictions enzymes and inserted into the pRenilla vector between the Bglll and EcoRV restriction sites. Mutation of the AUG107and AUG158in the SARS-CoV-2 and MERS-CoV gRNA, respectively, and the mutation of the UAA triplet at position 133 in SARS-CoV-2 have been performed by consecutive PCRs with specific primers (data not shown) to generate the mut-AUG107, mut-AUG158and uORF-phase constructs. The resulting PCR products were digested with the BamHI restriction enzyme and inserted into the pRenilla vector between the Bglll and BamHI restriction sites. All DNA constructs were verified by DNA sequencing.

[0244] 2.2. In Vitro Transcription

[0245] The four combinations — capped / polyadenylated (+ / +), capped / non-polyadenylated (+ / -), uncapped / polyadenylated (- / +) and uncapped / non-polyadenylated (- / -) — were obtained by in vitro transcription using the linear template of pRenilla vector by digestion either at the Xbal (non-polyadenylated RNAs) or at the EcoRI restriction site (polyadenylated RNAs). RNA transcription was performed from 1 pg of linear DNA template in transcription buffer (40 mM Tris-HCl (pH 7.5), 6 mM MgCh, 2 mM spermidine and 10 mM NaCl) in the presence of 40U of T7 RNA polymerase (Promega), 40 U ofRNAsin (Promega), 1.6 mM of each ribonucleotide triphosphate and 10 mM DTT. For capped mRNAs, the rGTP concentration was reduced to 0.32 mM, and m7-GpppG cap analog (New England Biolabs) was added at a concentration of 1.28 mM. The transcription reaction was carried out at 37 °C for 1 h 30, then treated for 30 min with the RQ1 DNAse (Promega). mRNAs were isolated using NucleoSpin RNA XS purification columns (Macherey Nagel). The integrity of RNA was checked by electrophoresis on non-denaturing 1% agarose gel and the concentration was determined by reading the absorbance using Nanodrop technology.

[0246] 2.3. In-Vitro Translation Assays

[0247] Nuclease-treated Flexi Rabbit Reticulocytes lysate (RRL) or untreated RRL (Promega), supplemented as previously described [90,91], were programmed with 5 or 10 fmol of in vitro synthetized mRNAs in the presence of 75 mM KC1, 0.5 mM MgOAc, 2 mM DDT and 20pM of each amino acid for 30 min at 30 °C. For radioactive labeling, 0.25 mCi / mL of [35S] methionine was added to the reaction mix. Translation products were then stopped in either Renilla lysis-juice buffer (PJK biotech) for luciferase assay or in Laemmli sample buffer (4% SDS, 10% P-mercaptoethanol, 20% glycerol, 0.004% bromophenol Blue, 0.125 M Tris-HCl pH 6.8) and resolved by 12% SDS-PAGE. The gel was dried and quantified with a Molecular Dynamics PhosphoImager.

[0248] The L-protease from Foot-and-Mouth Disease Virus (FMDV) was prepared in RRL as previously described

[0087] , L-protease (0.2 μL and 0.4μL ), hippuristanol (0.15, 0.3 and 0.6 pM) and the cap analog (IpM) were incubated 10 min in the RRL before RNA addition.

[0249] 2.4. Renilla Luciferase Activity

[0250] Renilla luciferase activity was measured using the Renilla- Juice luciferase assay (PJK GmbH, Kleinblittersdorf, Germany) following the manufacturer instructions on a LUMIstar apparatus (BMG LAB TECH, Champigny-sur-Marne, France) or on a Mithras LB 940 (Berthold, Thoiry, France).

[0251] 2.5. Western-Blot against elF 4G

[0252] Proteins from mock or L-protease-treated RRL extracts were separated by a 7.5% SDS- PAGE. The proteins were transferred onto polyvinylidene difluoride membranes (Boehringer Mannheim, Ingelheim am Rhein, Germany). Blots were incubated first with antibody against eIF4G (#2617 Cell Signaling Technology, Danvers, Massachusetts, USA) for 16 h at 4 °C, then with an anti -Rabbit IgG-Peroxidase antibody (Sigma Aldrich, Saint-Louis, MO, USA) for 2 h. The chemiluminescence signal was detected using an Pierce ™ ECL reagent (Thermofisher, Waltham, MA, USA) in the Chemidoc Imager (Biorad , Hercules, CA, USA).

[0253] 2.6. Cell Culture and RNA Transfection lurkat T-cell line, obtained from ATCC, was cultured in RPMI-1640 medium (Life Technologies), supplemented with 10% fetal calf serum, penicillin, streptomycin, Hepes pH 7.5, sodium pyruvate and L-glutamine. Cells were incubated at 37 °C in a 5% CO2 atmosphere.

[0254] For RNA transfection, 5.10(5) cells were resuspended in 10μL of buffer R (Life technology) in the presence of 500 fmol of capped and polyadenylated mRNAs, and immediately transfected using the Neon transfection kit (Life technology, Carlsbad, CA, USA) according the manufacturer instructions. Cells were incubated in RPMI medium for 90 min at 37 °C, washed twice in PBS and split in two pools to measure luciferase activities and to extract cytoplasmic RNAs.

[0255] 2.7. RNA Extraction and RT-qPCR

[0256] RNAs were isolated using the NucleoSpin RNA extraction kit according the manufacturer instructions (Macherey -Nagel, Duren, Germany) and quantified using a nanodrop 2000 spectrophotometer (Thermofisher, Waltham, MA, USA). Reverse transcription of 250 ng of cytoplasmic RNAs was performed using qScript kit (Quanta Bio, Beverly, MA, USA ). mRNA quantification was performed by quantitative PCR with the ONEGreen® FAST QPCR PREMIX (Ozyme, Saint-Cyr-l'Ecole, France) according to the manufacturer instmctions. Renilla luciferase (Renilla forward TGGACAATAACTTCTTCGTGAAAAC (SEQ ID N°9) / Renilla reverse GCTGCAAATTCTTCTGGTTCTAA) (SEQ ID N°10) was amplified in parallel with the endogenous housekeeping gene glyceraldehyde 3 -phosphate dehydrogenase (GAPDH) (GAPDH forward (Human) CGACAGTCAGCCGCATCTT (SEQ ID N°l l) / GAPDH reverse (Human) CCCCATGGTGTCTGAGCG) (SEQ ID N°12). The relative copy numbers of Renilla cDNAs were compared to GAPDH using x-ACt(where x corresponds to the experimentally calculated amplification efficiency of each primer couple).

[0257] 2.8. Sequence Alignment

[0258] The 5'UTRs of the SARS-CoV-1 (NC_004718.3), MERS-CoV (NC_038294) and SARS-CoV-2 (NC_045512.2) gRNAs were analyzed with a Multiple Sequence Comparison by Log-Expectation (MUSCLE) using the default parameters

[0092] ,

[0259] Results

[0260] 3.1. Translation Initiation Efficiency Mediated by the SARS-CoV-2 5'UTRs

[0261] During infection, SARS-CoV-2 generates at least 10 different mRNAs that harbor unique 5'UTRs in terms of length, structure and context of their AUG initiation site. In order to investigate further the role of these 5’UTRs in translational control, we have cloned each of the viral 5'UTR upstream of a reporter gene coding for the Renilla luciferase into the pRenilla vector [88,89,93] (Figure 3 A). The nucleotide triplet downstream to the TIS has been conserved to maintain the SARS-CoV-2 original Kozak context. As a control, we have used the 5'UTR of the globin mRNA, which is known to promote translation initiation in a very efficient manner. Capped and polyadenylated RNAs have been produced in vitro to program the rabbit reticulocytes lysate (RRL) in the presence of S35-methionine. Protein production was quantified on a phosphoImager after an SDS-PAGE resolution (Figure 3B). For most of the transcripts, expression was as efficient as that generated by the 50 nt. of the 0-globin 5'UTR (NC_000011.10; Figure 3B compare lanes 4-7, 9 and 11 with lane 2). Interestingly, the 5’UTRs derived from ORFl-ab, ORF-6 and ORF-7b promoted a higher level of expression than from the globin mRNA reporter gene (Figure 3B lanes 3, 8 and 10); this was not expected considering that these viral 5'UTRs are the longest and the most structured of the series (Figure 2 and Data not shown). We were also surprised to find that translation of ORF-3a, ORF-S, ORF-E and ORF-6 was still very efficient despite the fact that their AUG start codons are in a poor Kozak context (with a cytosine in -3 and / or an uracil in +4; Data not shown).

[0262] Quantification of protein production was also performed by measurement of the luciferase activity (Figure 3C). It should be remembered that the first amino acid downstream to the methionine codon was variable for each construct as we conserved the Kozak context of the original TIS (Figure SI). Thus, this N-terminal modification could have an impact on the activity of the luciferase; the same samples have also been quantified by luciferase assay. As the results obtained by reading of the luciferase assays were consistent with S35-methionine quantification (compare Figures 3B and 3C), we assumed that this N-terminal modification did not impact significantly the enzymatic activity of luciferase and the latter has been used as a readout for protein production for the remainder of this study.

[0263] Next, we translated the different mRNAs into the untreated RRL, which represents an in vitro competitive translation system due to the presence of endogenous mRNAs that compete for the translational apparatus

[0089] , In such a system, translation initiation mediated by the majority of the SARS-CoV-2 5'UTRs was further enhanced in comparison to the expression mediated by the globin 5'UTR (Figure 3D). Once again, and consistent with the RRL results, translation from the ORF-lab 5'UTR was the most efficient. This very high level of translation of viral RNAs in the untreated RRL suggests that they have the intrinsic ability to recruit ribosomes in a competitive environment. To go further, the mRNAs have been electroporated into cells and the protein expression level has been measured by luciferase assay and normalized to the quantity of RNA by RT-qPCR. The results showed in Figure 3E are consistent with the data obtained in the RRL systems. Taken together, our data show that the 5'UTRs of the SARS- CoV-2 have the ability to promote a high level of translation both in vitro and ex-vzvo, with the 5'UTR0RFlab(gRNA) sequence being the most efficient of all.

[0264] 3.2. Translation Efficiency from MERS-CoV gRNA 5'UTR Differs from SARS-CoV gRNA 5’UTRs.

[0265] We next wondered whether a high level of translation could also be observed with RNAs derived from closed relative strains, i.e., the SARS-CoV-1 [94-96] and the MERS-CoV [97- 99], The 5'UTR of the SARS-CoV-1 gRNA is 264 nt. long and shares 90% of its identity with the sequence of the SARS-CoV-2 (Figures 4A and Data not shown). Once more, the global RNA structure of the 5'UTR is also conserved [73,74,77], which could indicate that expression initiated from the 5'UTR of the gRNA from both SARS-CoV strains could be similar. In contrast, the MERS-CoV gRNA’s 5'UTR is slightly longer (277 nt.) and more distant from SARS-CoV sequences as it shares only -60% of its identity with type 1 and type 2 (Figures 4A and S2), which could also suggest a divergence in translational efficiency. To directly test this hypothesis, we have used the pRenilla reporter gene harboring either the leader sequence, which represents the shorter 5'UTR (named leader), or the 5'UTR of the SARS- and the MERS-CoV gRNA (named 5'UTRORFlabin the rest of the manuscript) (Figure 4B). Capped and polyadenylated mRNAs were generated by in vitro transcription and translated in the RRL (Figure 4C) or electroporated into Jurkat cells (Figure 4D). The products of expression were quantified by luciferase assays and normalized to the expression mediated by the globin 5'UTR, which served as a positive control. Consistent with our previous results, the 5'UTR0RFlabof SARS-CoV-2 gRNA promoted strong protein production (Figure 4C,D). As expected, a similar expression profile was observed when translation was driven by the 5'UTR0RFlabof the SARS- CoV-1, both in the RRL and in cells (Figure 4C,D), confirming that the translational characteristics are well conserved between the two strains. In contrast, although the leader sequence of MERS-CoV was also efficient to drive translation in the RRL, it still remained lower than that of the SARS-CoV transcripts (Figure 4C). This difference was even sharper with the 5'UTR0RFlabof MERS-CoV, which showed a decrease of up to 30% when compared to globin expression (Figure 4C). These differences were also observed when the reporter mRNAs were transfected in cell lines (Figure 4D). Our data show that the translation characteristics of the 5'UTR0RFlabare conserved between the two SARS-CoV strains but differ with MERS-CoV. This indicates that divergences in sequence conservation are also observed in terms of translational efficiency.

[0266] 3.3. SARS-CoV-2 Translation Initiation Requires the Cap Structure and the Components of eIF4F Complex

[0267] Data obtained so far have pointed out that translation of the gRNA of the SARS-CoV-2 is very efficient, both in vitro and ex vivo, but the molecular mechanism by which this occurs remains to be determined. Surprisingly, the gRNA is the longest and most structured transcript, which should, a priori, represent a physical barrier for linear ribosomal scanning. On the other hand, the viral gRNA is capped and polyadenylated, which is a strong argument for a capdependent mechanism of translation initiation. This is also in agreement with previous studies showing that addition of cap analog to the RRL resulted in a strong reduction of translation driven by the 5’UTR of the bovine CoV strain [100,101], Furthermore, the destabilization of the eIF4F complex also results in the inhibition of viral replication of MERS-CoV and HCoV- 229E [102,103], Although these studies suggest a cap-dependent mechanism of translation for coronavirus mRNAs, this has not been experimentally established. On the other hand, the structural features of the 5'UTRORFlab(gRNA), as well as the presence of a uORF and an AUG start codon located in a four-way junction RNA structure, could suggest the presence of an active IRES motif within the 5’UTR [49,82-85], Therefore, in order to distinguish between these two possibilities, we decided to further investigate the molecular mechanism by which translation initiation occurs on the SARS-CoV-2 gRNA.

[0268] We first looked at the effects of both the cap and the poly(A) tail structures in the translation of SARS-CoV-2 mRNAs. In order to avoid the bias of RNA stability caused by the absence of both structures, we performed our study in in vitro translation systems. For this, we produced different combinations of capped, uncapped, polyadenylated and non-polyadenylated transcripts harboring the 5'UTR of the globin, the 5UTR0RFlabor the leader sequence of SARS- CoV-2. Both RRL (Figure 5A) and untreated RRL (Figure 5B) were programmed for 30 min and expression of the Renilla was quantified by luciferase assays. As expected, the synergic effect of the combination of the cap structure and the poly(A) tail was observed with the RNA control (globin 5'UTR). Enhancement of translation provided by these two elements was even amplified in the competitive untreated RRL, which is an experimental system known to recapitulate faithfully cap / poly(A) synergy

[0089] , Expression initiated by the leader sequence or the 5'UTR0RFlabwas highly dependent on the presence of the cap structure with a 10-fold stimulation over the uncapped transcripts (Figure 5B). In contrast, we were surprised to find that the addition of the poly(A) tail on the SARS-CoV-2 mRNAs did not add any supplementary translational advantage over the non-polyadenylated mRNAs. This shows an unambiguous requirement for the m7GTP cap structure but no significant effect of the poly(A) tail. In addition, this denotes a major difference with canonical globin translation regarding the requirement for the 3’ poly (A) tail.

[0269] We decided to continue our investigation to look at the role of the initiation factors that are required for SARS-CoV-2 translation with a particular focus on the cap-binding complex eIF4F (Figure 6A). This complex is formed by the association of three initiation factors: eIF4E, eIF4A and eIF4G and its role is to bind both to the m7GTP cap structure and to the ribosome [2] Addition of cap analog to the RRL chelates eIF4F by competitive binding and sequesters it from binding to the 5’ end of the mRNAs (Figure 6A)

[0104] , As expected, the addition of the cap analog in our translation assay resulted in a strong repression of globin translation (Figure 6B) and a similar effect was observed on both the 5’UTRORFlaband leader of the SARS-CoV-2 transcripts, confirming that the eIF4F complex is needed for their expression.

[0270] Next, in order to distinguish whether the whole eIF4F, or parts of it, are needed, we decided to specifically focus on the independent role of both eIF4A and eIF4G, which are core subunits of eIF4F. eIF4G can be targeted by viral proteases and eIF4A can be specifically inhibited by some chemicals (Figure 6A). We first studied the dependence on eIF4G by using the L protease from the foot-and-mouth-disease virus [105,106], This enzyme cleaves eIF4G to yield a N-terminal domain able to bind to eIF4E and a C-terminal domain (called plOO), which harbors the interacting domains with eIF4A and eIF3

[0107] , Functionally, the cleavage of eIF4G inhibits cap-dependent transcripts but does not affect, and even stimulates, translation of mRNAs bearing an IRES

[0108] , We have added in-vitro-translated L protease to the untreated RRL that resulted in the cleavage of eIF4G (Figure 6C) and we observed different effects on the reporter constructs assayed. As expected, cap-dependent translation driven by globin 5'UTR was inhibited (Figure 6D), whereas the encephalomyocarditis virus (EMCV) IRES-mediated protein synthesis was slightly stimulated (Figure 6E) as previously described

[0087] , Cleavage of eIF4G resulted in the inhibition of expression from both SARS-CoV-2 5'UTR0RFlaband leader sequence mRNAs (Figure 6F) and to a similar magnitude as that for globin, suggesting that translation initiation from SARS-CoV-2 5'UTRs depends on a mechanism that requires the integrity of eIF4G.

[0271] Finally, we evaluated the requirement for the DEAD box RNA helicase eIF4A, which is the third partner of the eIF4F complex and is involved in RNA unwinding and scanning

[0109] , Indeed, chemical and enzymatic probing analysis of the SARS-CoV-2 5'UTR0RFlab[73,74] has revealed a high level of RNA secondary structures (Figure 2) that may interfere with ribosome scanning. To test this hypothesis, we used a natural chemical inhibitor of the eIF4A RNA- binding activity called hippuristanol (Figure 6A)

[0110] , Addition of increasing amounts of hippuristanol in the RRL inhibited globin cap-dependent translation in a dose-dependent manner, whereas it did not interfere with expression of a mRNA driven by the Hepatitis C Virus (HCV) IRES (Figure 6G), which does not require eIF4A

[0111] , The RRL was then programmed with reporter genes containing SARS-CoV-2 5'UTR0RFlabor leader sequence RNA constructs and this showed that initiation on both of these RNAs was repressed upon addition of hippuristanol (Figure 6G) and the extent of translation repression was comparable to that obtained for globin mRNAs.

[0272] Taken together, our data indicate that translation from the SARS-CoV-2 5'UTR0RFlabrequires the activity of each component of the eIF4F complex, namely eIF4E, eIF4G and eIF4A, which is consistent with a cap-dependent initiation mechanism.

[0273] 3.4. uORF Downregulates the Translation Efficiency ofgRNA

[0274] The 5'UTRORFlabof the SARS-CoV-2 (gRNA) harbors a potential uORF of nine amino acids that starts at the AUG107triplet and finishes at the UAA triplet located at position 134 (Figures 2 and 7A). uORFs are cv.s-acting elements located in the 5'UTR that impact on the translation efficiency of the mRNA. When these uORFs are translated by incoming ribosomes from the 5' end, this often results in the decrease of translation initiation from the main downstream ORF [27,112-115], However, in some particular cases, the presence of uORFs can also act as enhancers of protein production, as it was described with some stress-related mRNAs [29,114,116,117],

[0275] In the case of the SARS-CoV-2 gRNA, ribosomal profiling data have suggested that some ribosomes recognize and pause at the AUG107codon

[0086] , However, formal proof that this uORF is translated and the level at which it is expressed remain to be determined. To test this hypothesis, we introduced two mutations in the pSARS-CoV-2 5 UTR0RFlab-Renilla to change the AUG107triplet into an UAA triplet (Mut-AUG107) and to delete the stop codon (UAA134) in order to align AUG107in the same reading frame as the Renilla ORF (uORF phase). The resulting RNAs have been synthesized by in vitro transcription and translated into the RRL in the presence of S35-methionine. Data are presented in Figure 7 and show that mutation of the AUG107triplet resulted in a slight stimulation of expression of the main ORF (Renilla) (Figure 7B lane 3), confirming that this AUG triplet was recognized as an initiation site by the scanning ribosome. This was confirmed by the second mutation (deletion of the UAA), which resulted in an increased expression of Renilla (Figure 7B lane 4, denoted by the star). Altogether, our data unambiguously show that the uORF located in the 5'UTR0RFlabwas translated in the RRL, but the effect on protein expression, i.e., both production of the short peptide and increased production of Renilla, remained relatively modest. In order to better appreciate the magnitude of this effect, we have performed similar experiments on the 5UTR0RFlabof the MERS-CoV gRNA as it also contains an uORF starting at the AUG158triplet, which is located closer to the AUG start codon of ORF-lab (Figure 7A). To evaluate its role on mRNA translation, we have also mutated the AUG158triplet. The resulting mRNA was translated in the RRL and protein products were analyzed on SDS-PAGE and quantified with a phosphoImager. We observed that mutation of the AUG158triplet induced a strong expression of the main ORF, which was stimulated by up to three times when compared to the parental 5'UTR (Figure 7C). This stimulation was also observed when the reporter mRNAs were transfected in cell lines (Figure 7D). These results confirmed important differences in translational control exerted by the uORFs in the coronavirus family with a moderate attenuation of translation in SARS-CoV-2 compared to a more pronounced impact on the MERS-CoV 5'UTR.

[0276] 4. Discussion

[0277] Infection by SARS-CoV-2 generates a gRNA and at least nine sgRNAs, which all start with a 75 nt. common leader sequence

[0071] , Each of these transcripts harbor a unique 5’UTR, which is composed of the shared leader sequence followed by an RNA region that varies in length (between 0 to 190 nt. (Table 1)). Thus, the resulting viral 5'UTRs have different degrees of RNA structures and some of them contain c / .s-acting elements, such as an uORF, which is known to have an impact on translation initiation efficiency. This set the rationale for this study aimed at investigating the translational properties of all virally encoded mRNAs. To answer to this question, we showed that viral 5'UTRs show significant variations of expression although they all exhibit a high level of activity compared to globin 5'UTR control. Importantly, the high and relative levels of expression between viral mRNAs were maintained regardless of the experimental systems used (RRL, competitive RRL and cells) (Figure 3), with the 5'UTR0RFlab(gRNA) being the most efficient of all. This is rather surprising considering that the 5'UTR0RFlabis the longest of the series (265 nt.), with multiple stable hairpin RNA structures and, above all, the presence of the uORF (Figure 2). A priori, these structural features should represent hurdles for ribosomal binding and scanning and one would predict a poor level of protein expression. However, this is clearly not the case as expression was revealed to be very efficient and conserved between the two SARS-CoV strains (Figure 4). This suggested to us that the SARS-CoV-2 5'UTR0RFlabcould use an alternative cap-independent mechanism; such an assumption was also strengthened by the presence of the AUG start codon in a four-way junction, which is a structural conformation that was previously described for HCV IRES

[0118] , This prompted us to look for the requirement of the viral gRNA in the initiation factors involved in cap-driven translation initiation. We showed that both the cap structure and the eIF4F complex are necessary to initiate translation, which strongly suggest a cap-dependent mechanism (Figures 5 and 6). We can assume that, after ribosomal attachment to the cap structure, the PIC scans the viral 5'UTR to reach the initiation codon as eIF4A is required (Figure 6G) and, above all, the uORF is translated (Figure 7). However, we cannot rule out that ribosomal shunting could occur through the 5'UTR to bypass some hairpin RNA structures [119-121] and contribute to this high level of translation. This mechanism usually needs additional proteins

[0121] and this will require further studies to determine its implication in SARS-CoV-2 translation initiation.

[0278] In the canonical translation initiation mechanism, the interaction between the poly(A) binding protein (PABP) and eIF4G [122,123] brings the 5'- and 3'-ends of the mRNA together and forms a mRNA’s circularization called the closed-loop model [124,125], which promotes translation [89,126], Interestingly, in our system, which is able to recapitulate the cap / poly(A) synergy

[0089] , the poly(A) tail did not provide any translational advantage to the mRNAs that harbor the SARS-CoV-2 5'UTR0RFlabwhen compared to globin 5'UTR, which uses a strict canonical cap-dependent translation initiation mechanism (Figure 5). This particularity is quite unusual in the eukaryotic kingdom and this raises the question of whether this closed-loop conformation takes place on mRNAs that harbor the SARS-CoV-2 5'UTR. The poly(A) tail requirement should be further investigated in the future to determine if the PAPB is necessary to promote initiation and still interacts with eIF4G. To our knowledge, a neutral influence of the poly(A) tail, in translation, has never been reported before. Viral and cellular mRNAs without a poly(A) tail have been described but they use alternative and specific cA-acting elements to bring the 5'- and 3'-ends of the mRNA together [127-132], Analyses of the formation of 48S PIC in RRL through a sucrose gradient have indicated that it is almost absent on mRNAs harboring the SARS-CoV-2 5'UTR but not with the EMCV IRES

[0080] , suggesting that the initiation process on SARS-CoV-2 is not canonical. In SARS-CoV-2 infected cells, the size of the poly(A) tail is quite short (47 nt. for median length) and is longer on the gRNA than on the sgRNAs

[0071] , Interestingly, during bovine CoV infection, the length of the poly(A) tail changes from ~45 nt. immediately after virus entry to ~65 nt. at 6 to 9 h post-infection

[0133] , These quick modifications of the length are reminiscent of the translational control that takes place during early oocyte / embryo development

[0134] , Although we did not notice a requirement for the poly(A) tail in SARS-CoV-2 translation in the RRL, this does not exclude that the poly(A) tail of SARS-CoV-2 mRNAs may regulate translation efficiency, mRNA stability and / or mRNA localization in infected cells.

[0279] The exact mechanism by which the SARS-CoV-2 5'UTRs drive the high levels of expression is puzzling considering the structural features of the gRNA; nevertheless, this characteristic could turn out to be a real benefit for viral replication in infected cells. Indeed, in the early phases of infection, the viral nspl interacts with the 18S ribosomal RNA in the mRNA entry channel of the ribosome and imposes a blockage by steric hindrance, leading to a global inhibition of mRNA translation [135-137], However, viral mRNAs can escape this nspl- mediated repression via a complex interplay between the leader sequence, especially the SL1 RNA structure [78,80,81,137], which is able to interact with nspl [80,138], It has been shown that, at low concentrations, nspl is able to stimulate the expression of mRNA reporters that harbor the SL 1 sequence in cells

[0081] but not in the RRL

[0080] , which is not a competitive system. This, along with our data, suggests that SARS viral RNAs have the ability to compete very efficiently with cellular transcripts for the translational apparatus. Thus, it would be very interesting to assay the role of nspl in the untreated RRL as well as in infected cells.

[0280] Finally, the expression of the gRNA is also regulated by an uORF localized within its 5'UTR, some 120 nucleotides upstream from the authentic AUG initiation codon. We first showed that this uORF was recognized by scanning ribosomes and translated into a short peptide whose role remains to be determined. In addition, mutation of the start AUG codon of the uORF induced only a mild stimulation of the expression of the main reading frame. This contrasts with the situation obtained with the MERS-CoV, in which we showed that this uORF exerts a strong control on translation (Figures 7C and 7D). This is puzzling as the uORF is conserved, suggesting its importance in the control and regulation of protein synthesis despite having different effects on the flux of incoming ribosomes.

[0281] Genome-wide sequencing of 5’UTR has revealed that uORFs are much more pervasive in the genome than initially described, with an occurrence of about 50% in mammalian mRNAs [139,140], These uORFs can be located within non-coding RNAs, within the 5’ and 3’ UTRs or they can also be overlapping with the main ORF, either in-frame or out-of-frame with the main protein product

[0141] , According to their localization, these uORFs regulate gene expression in at least three different ways: (i) by imposing a sharp translational control on the main ORF; (ii) by producing functional micro-peptides and (iii) generating truncated / extended isoforms of the main protein product.

[0282] In the case of the uORF present in the SARS / MERS coronavirus, it is clearly located within the 5’UTR0RFlaband encodes a putative short peptide of 9-11 amino acids, which does not appear conserved amongst the different members (Figure S3). Thus, it suggests that this uORF regulates expression of the main protein product by throttling down the flux of incoming ribosomes. This can happen by either stalling the 80S ribosomal complex that forms on the encoded short reading frame, thus creating a roadblock for scanning ribosomes or, alternatively, the short reading frame can also be a waylay for scanning pre-initiation complexes

[0022] , As the same conserved uORF has a different impact on expression from the SARS-CoV-1 and -2 compared to the MERS-CoV, this could reflect the fact that two distinct mechanisms are at play. This is an important point that will be addressed in the future. In any case, this uORF must be a key regulator of viral translation and replication as it is widely conserved. Indeed, this uORF is highly conserved from different coronaviruses

[0142] and recent ribosome profiling analyses have confirmed that its AUG initiation codon is recognized by ribosomal complexes during both Mouse Hepatitis Virus (MHV) and SARS-CoV-2 infection [86,143], One study has focused on the physiological function of the peptide issued by this uORF in MHV infection. For that, the authors mutated the AUG-initiated uORF in the viral genome, showing that the virus was viable in cell culture. However, serial passage of this mutant variant resulted in a reversion to an intact uORF, indicating that this uORF must play a beneficial role in virus survival in cell culture

[0142] ,

[0283] To summarize, our data strongly suggest that translation of the SARS-CoV-2 mRNAs involves an unconventional cap-dependent mechanism that involves c / .s-acting RNA elements such as the structure of the leader, the length of the poly(A) tail and the role of the uORF. Taken together, these elements must probably functionally interact with each other in order to regulate the flow of ribosomes on the viral mRNAs.

[0284] EXAMPLE 2

[0285] In order to compare the translation initiation efficiency mediated by the SARS-CoV-2 genomic RNA and several SARS-CoV-2 mRNA vaccines (Pfizer-BioNTech BNT162b2 and Modema mRNA-1273) we cloned each 5' UTR upstream of a reporter gene encoding the Renilla luciferase into the pSF2 vector (see figure 8). The 5 ’ UTRs of the mRNA vaccines were designed based on previous publications (see (1) Xia, X. Detailed dissection and critical evaluation of the Pfizer / BioNTech and Moderna mRNA vaccines. Vaccines 9, 734 (2021). (2) Jeong, D.-E. et al. Assemblies of putative SARS-CoV2-spike-encoding mRNA sequences for vaccines BNT-162b2 and mRNA-1273. docx, https: / / virological.org / t / assemblies-of-putative- sars-cov2-spike-encoding-mma-sequences-for-vaccines-bnt-162b2-and-mrna-1273 / 663 (2021). and(3) World Health Organization. Messenger RNA encoding the full-length SARS- CoV-2 Spike Glycoprotein, https: / / web. archive. org / web / 20210105162941 / https: / / mednet- communities.net / inn / db / media / docs / 11889.doc (2020).). As a control, we have used the 5' UTR of the globin mRNA. Capped and poly adenylated RNAs were generated in vitro and then translated in the rabbit reticulocyte lysate (RRL). The quantification of protein production was performed by measuring the luciferase activity. Interestingly, the 5' UTRs derived from ORFl-ab promoted a higher level of reporter gene expression compared to both mRNA vaccines and globin 5'UTRs. These results are consistent with our previous findings, demonstrating the ability of the 5'UTR derived from ORFlab of SARS-CoV-2 genomic RNA to promote high level of translation. Table 2: Useful nucleic acid sequences for practicing the invention REFERENCES:

[0286] Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.

[0287] 1. Merrick, W.C.; Pavitt, G.D. Protein Synthesis Initiation in Eukaryotic Cells. Cold Spring Harb. Perspect. Biol. 2018, 10, a033092.

[0288] 2. Pelletier, J.; Sonenberg, N. The Organizing Principles of Eukaryotic Ribosome Recruitment. Annu. Rev. Biochem. 2019, 88, 307-335.

[0289] 3. Kapp, L.D.; Lorsch, J.R. GTP-dependent recognition of the methionine moiety on initiator tRNA by translation factor eIF2. J. Mol. Biol. 2004, 335, 923-936.

[0290] 4. Pelletier, J.; Schmeing, T.M.; Sonenberg, N. The multifaceted eukaryotic cap structure. Wiley Interdiscip. Rev. RNA 2021, 12, el636.

[0291] 5. LeFebvre, A.K.; Korneeva, N.L.; Trutschl, M.; Cvek, U.; Duzan, R.D.; Bradley, C.A.; Hershey, J.W.; Rhoads, R.E. Translation initiation factor eIF4G-l binds to eIF3 through the eIF3e subunit. J. Biol. Chem. 2006, 281, 22917-22932.

[0292] 6. Villa, N.; Do, A.; Hershey, J.W.; Fraser, C.S. Human eukaryotic initiation factor 4G (eIF4G) protein binds to eIF3c, -d, and -e to promote mRNA recruitment to the ribosome. J. Biol. Chem. 2013, 288, 32932-32940.

[0293] 7. Kumar, P ; Hellen, C.U.; Pestova, T.V. Toward the mechanism of eIF4F-mediated ribosomal attachment to mammalian capped mRNAs. Genes Dev. 2016, 30, 1573-1588.

[0294] 8. Hinnebusch, A.G. Structural Insights into the Mechanism of Scanning and Start Codon Recognition in Eukaryotic Translation Initiation. Trends Biochem. Sci. 2017, 42, 589-611.

[0295] 9. Advani, V.M.; Ivanov, P. Translational Control under Stress: Reshaping the Translatome. Bioessays 2019, 41, e 1900009.

[0296] 10. Proud, C.G. Phosphorylation and Signal Transduction Pathways in Translational Control. Cold Spring Harb. Perspect. Biol. 2019, 11, a033050.

[0297] 11. Wek, R.C.; Jiang, H.Y.; Anthony, T.G. Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans. 2006, 34 (Pt. 1), 7-11.

[0298] 12. Leppek, K.; Barna, M. An rRNA variant to deal with stress. Nat. Microbiol. 2019, 4, 382-383.

[0299] 13. Kozak, M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986, 44, 283-292.

[0300] 14. Kozak, M. An analysis of 5 '-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987, 15, 8125-8148. 15. Kozak, M. The scanning model for translation: An update. J. Cell Biol. 1989, 108, 229- 241.

[0301] 16. Kozak, M. Initiation of translation in prokaryotes and eukaryotes. Gene 1999, 234, 187— 208.

[0302] 17. Kozak, M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 1987, 196, 947-950.

[0303] 18. Kozak, M. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res. 1981, 9, 5233-5252.

[0304] 19. Kozak, M. Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo Nature 1984, 308, 241-246.

[0305] 20. Pisarev, A.V.; Kolupaeva, V.G.; Pisareva, V.P.; Merrick, W.C.; Hellen, C.U.; Pestova, T.V. Specific functional interactions of nucleotides at key -3 and +4 positions flanking the initiation codon with components of the mammalian 48S translation initiation complex. Genes Dev. 2006, 20, 624-636.

[0306] 21. Hussain, T.; Llacer, J.L.; Fernandez, I S.; Munoz, A.; Martin-Marcos, P .; Savva, C.G.; Lorsch, J.R.; Hinnebusch, A.G.; Ramakrishnan, V. Structural changes enable start codon recognition by the eukaryotic translation initiation complex. Cell 2014, 159, 597-607.

[0307] 22. Hinnebusch, A.G.; Ivanov, I.P., Sonenberg, N. Translational control by 5 ' - untranslated regions of eukaryotic mRNAs. Science 2016, 352, 1413- 1416.

[0308] 23. Noderer, W.L.; Flockhart, R.J ; Bhaduri, A.; Diaz de Arce, A. J.; Zhang, J.; Khavari, P.A.; Wang, C L. Quantitative analysis of mammalian translation initiation sites by FACS-seq. Mol. Syst. Biol. 2014, 10, 748.

[0309] 24. Xia, X. The +4G site in Kozak consensus is not related to the efficiency of translation initiation. PLoS ONE 2007, 2, el88.

[0310] 25. Volkova, O.A.; Kochetov, A.V. Interrelations between the nucleotide context of human start AUG codon, N-end amino acids of the encoded protein and initiation of translation. J. Biomol. Struct. Dyn. 2010, 27, 611-618.

[0311] 26. Chen, H.H.; Tam, W.Y. uORF-mediated translational control: Recently elucidated mechanisms and implications in cancer. RNA Biol. 2019, 16, 1327-1338.

[0312] 27. Johnstone, T.G.; Bazzini, A.A.; Giraldez, A. J. Upstream ORFs are prevalent translational repressors in vertebrates. EMBO J.. 2016, 35, 706-723.

[0313] 28. Wethmar, K. The regulatory potential of upstream open reading frames in eukaryotic gene expression. Wiley Interdiscip. Rev. RNA 2014, 5, 765-778. 29. Palam, L.R.; Baird, T.D.; Wek, R.C. Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. J. Biol. Chem. 2011, 286, 10939- 10949.

[0314] 30. Vattem, K.M.; Wek, R.C. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc. Natl. Acad. Sci. USA 2004, 101, 11269-11274.

[0315] 31. Zhou, D.; Palam, L.R.; Jiang, L.; Narasimhan, J.; Staschke, K.A.; Wek, R.C. Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions. J. Biol. Chem. 2008, 283, 7064-7073.

[0316] 32. Kozak, M. Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs. Mol. Cell. Biol. 1989, 9, 5134-5142.

[0317] 33. Babendure, J.R.; Babendure, J.L.; Ding, J.H.; Tsien, R.Y. Control of mammalian translation by mRNA structure near caps. Rna 2006, 12, 851-861.

[0318] 34. Pelletier, J.; Sonenberg, N. Photochemical cross-linking of cap binding proteins to eucaryotic mRNAs: Effect of mRNA 5' secondary structure. Mol. Cell. Biol. 1985, 5, 3222-3230.

[0319] 35. Pelletier, J.; Sonenberg, N. Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell 1985, 40, 515-526.

[0320] 36. Kozak, M. Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc. Natl. Acad. Sci. USA 1986, 83, 2850-2854.

[0321] 37. Parsyan, A.; Svitkin, Y.; Shahbazian, D.; Gkogkas, C.; Lasko, P.; Merrick, W.C.; Sonenberg, N. mRNA helicases: The tacticians of translational control. Nat. Rev. Mol. Cell Biol. 2011, 12, 235-245.

[0322] 38. Lai, M.C.; Wang, S.W.; Cheng, L ; Tam, W.Y.; Tsai, S.J.; Sun, H.S. Human DDX3 interacts with the HIV-1 Tat protein to facilitate viral mRNA translation. PLoS ONE 2013, 8, e68665.

[0323] 39. Soto-Rifo, R.; Rubilar, P.S.; Limousin, T.; de Breyne, S.; Decimo, D.; Ohlmann, T. DEAD-box protein DDX3 associates with eIF4F to promote translation of selected mRNAs. EMBO J. 2012, 31, 3745-3756.

[0324] 40. Hentze, M.W.; Caughman, S.W.; Rouault, T.A.; Barriocanal, J.G.; Dancis, A.; Harford, J.B.; Klausner, R.D. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science 1987, 238, 1570-1573.

[0325] 41. Hentze, M.W.; Rouault, T.A.; Caughman, S.W.; Dancis, A.; Harford, J.B.; Klausner, R.D. A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc. Natl. Acad. Sci. USA 1987, 84, 6730-6734.

[0326] 42. Gray, N.K.; Hentze, M.W. Iron regulatory protein prevents binding of the 43S translation pre-initiation complex to ferritin and eALAS mRNAs. EMBO J. 1994, 13, 3882-3891. 43. Muckenthaler, M.; Gray, N.K.; Hentze, M.W. IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal subunit by the cap-binding complex eIF4F. Mol. Cell 1998, 2, 383-388.

[0327] 44. Friebe, P.; Lohmann, V.; Krieger, N.; Bartenschlager, R. Sequences in the 5 ' nontranslated region of hepatitis C virus required forRNA replication. J. Virol. 2001, 75, 12047-12057.

[0328] 45. Bieniasz, P.; Telesnitsky, A. Multiple, Switchable ProteimRNA Interactions Regulate Human Immunodeficiency Virus Type 1 Assembly. Annu. Rev. Virol. 2018, 5, 165-183.

[0329] 46. Malone, B.; Urakova, N.; Snijder, E.J.; Campbell, E.A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 2022, 23, 21-39.

[0330] 47. Jang, S.K.; Krausslich, H.G.; Nicklin, M.J ; Duke, G.M.; Palmenberg, A C.; Wimmer, E. A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 1988, 62, 2636-2643.

[0331] 48. Pelletier, J.; Sonenberg, N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988, 334, 320-325.

[0332] 49. Martinez-Salas, E.; Francisco-Velilla, R.; Fernandez-Chamorro, J.; Embarek, A.M. Insights into Structural and Mechanistic Features of Viral IRES Elements. Front. Microbiol. 2017, 8, 2629.

[0333] 50. Mailliot, J.; Martin, F. Viral internal ribosomal entry sites: Four classes for one goal. Wiley Interdiscip. Rev. RNA 2018, 9, doi:10.1002 / wma.l458.

[0334] 51. Kwan, T.; Thompson, S.R. Noncanonical Translation Initiation in Eukaryotes. Cold Spring Harb. Perspect. Biol. 2019, 11, a032672.

[0335] 52. Komar, A. A.; Hatzoglou, M. Cellular IRES-mediated translation: The war of ITAFs in pathophysiological states. Cell Cycle 2011, 10, 229-240.

[0336] 53. Yang, T H ; Wang, C.Y.; Tsai, H.C.; Liu, C.T. Human IRES Atlas: An integrative platform for studying IRES-driven translational regulation in humans. Database 2021, 2021, baab025.

[0337] 54. de Breyne, S.; Yu, Y .; Unbehaun, A.; Pestova, TV.; Hellen, C.U. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc. Natl. Acad. Sci. USA 2009, 106, 9197-9202.

[0338] 55. Pestova, T.V.; Hellen, C.U.; Shatsky, LN. Canonical eukaryotic initiation factors determine initiation of translation by internal ribosomal entry. Mol. Cell. Biol. 1996, 16, 6859-6869.

[0339] 56. Sizova, D.V.; Kolupaeva, V.G.; Pestova, T V.; Shatsky, I.N.; Hellen, C.U. Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs. J. Virol. 1998, 72, 4775-4782. 57. Pestova, T.V.; Lomakin, LB.; Hellen, C.U. Position of the CrPV IRES on the 40S subunit and factor dependence of IRES / 80S ribosome assembly. EMBO Rep. 2004, 5, 906-913.

[0340] 58. Kolupaeva, V.G.; Pestova, T.V.; Hellen, C.U.; Shatsky, LN. Translation eukaryotic initiation factor 4G recognizes a specific structural element within the internal ribosome entry site of encephalomyocarditis virus RNA. J. Biol. Chem. 1998, 273, 18599-18604.

[0341] 59. Wilson, J.E.; Pestova, T.V.; Hellen, C.U.; Sarnow, P. Initiation ofprotein synthesis from the A site of the ribosome. Cell 2000, 102, 511-520.

[0342] 60. Spahn, C.M.; Jan, E.; Mulder, A.; Grassucci, R.A.; Samow, P.; Frank, J. Cryo-EM visualization of a viral internal ribosome entry site bound to human ribosomes: The IRES functions as an RNA-based translation factor. Cell 2004, 118, 465-475.

[0343] 61. de Breyne, S.; Yu, Y.; Pestova, T V.; Hellen, C.U. Factor requirements for translation initiation on the Simian picomavirus internal ribosomal entry site. RNA 2008, 14, 367-380.

[0344] 62. Hashem, Y., des Georges, A.; Dhote, V.; Langlois, R.; Liao, H.Y.; Grassucci, R.A.; Pestova, T V ; Hellen, C.U.; Frank, J. Hepatitis-C-virus-like internal ribosome entry sites displace eIF3 to gain access to the 40S subunit. Nature 2013, 503, 539-543.

[0345] 63. Chamond, N.; Deforges, J.; Ulryck, N.; Sargueil, B. 40S recruitment in the absence of eIF4G / 4A by EMCV IRES refines the model fortranslation initiation on the archetype of Type II IRESs. Nucleic Acids Res. 2014, 42, 10373-10384.

[0346] 64. Stem-Ginossar, N.; Thompson, S.R.; Mathews, M.B.; Mohr, I. Translational Control in Virus-Infected Cells. Cold Spring Harb. Perspect. Biol. 2019, 11, a033001.

[0347] 65. Sajjanar, B ; Deb, R.; Raina, S.K.; Pawar, S.; Brahmane, M.P.; Nirmale, A.V.; Kurade, N.P.; Manjunathareddy, G.B.; Bal, S.K.; Singh, N.P. Untranslated regions (UTRs) orchestrate translation reprogramming in cellular stress responses. J. Biol. 2017, 65, 69-75.

[0348] 66. Godet, A.C.; David, F.; Hantelys, F.; Tatin, F.; Lacazette, E.; Garmy-Susini, B.; Prats, A.C. IRES Trans-Acting Factors, Key Actors of the Stress Response. Int. J. Mol. Sci. 2019, 20, 924.

[0349] 67. Jaafar, Z.A.; Kieft, J.S. Viral RNA structure-based strategies to manipulate translation. Nat. Rev. Microbiol. 2019, 17, 110-123.

[0350] 68. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B ; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727-733.

[0351] 69. Sola, L; Almazan, F.; Zuniga, S.; Enjuanes, L. Continuous and Discontinuous RNA Synthesis in Coronaviruses. Annu. Rev. Virol. 2015, 2, 265-288.

[0352] 70. Brant, A.C.; Tian, W.; Majerciak, V.; Yang, W.; Zheng, Z.M. SARS-CoV-2: From its discovery to genome structure, transcription, and replication. Cell Biosci 2021, 11, 136.

[0353] 71. Kim, D.; Lee, J.Y.; Yang, J.S.; Kim, J.W.; Kim, V.N.; Chang, H. The Architecture of SARS-CoV-2 Transcriptome. Cell 2020, 181, 914-921.el0. 72. Kim, D.; Kim, S.; Park, J.; Chang, H.R.; Chang, J.; Ahn, J.; Park, H.; Park, J.; Son, N.; Kang, G ; et al. A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome. Nat. Commun. 2021, 12, 5120.

[0354] 73. Miao, Z.; Tidu, A.; Eriani, G.; Martin, F. Secondary structure of the SARS-CoV-2 5'- UTR. RNA Biol. 2021, 18, 447-456.

[0355] 74. Lan, T.C.T.; Allan, M F.; Malsick, L.E.; Woo, J.Z.; Zhu, C.; Zhang, F.; Khandwala, S.; Nyeo, S.S.Y.; Sun, Y.; Guo, J.U.; et al. Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells. Nat. Commun. 2022, 13, 1128.

[0356] 75. Madhugiri, R.; Fricke, M ; Marz, M.; Ziebuhr, J. Coronavirus cis-Acting RNA Elements. Adv. Virus Res. 2016, 96, 127-163.

[0357] 76. Madhugiri, R.; Karl, N.; Petersen, D.; Lamkiewicz, K ; Fricke, M.; Wend, U.; Scheuer, R.; Marz, M.; Ziebuhr, J. Structural and functional conservation of cis-acting RNA elements in coronavirus 5'-terminal genome regions. Virology 2018, 517, 44-55.

[0358] 77. Yang, D.; Leibowitz, J.L. The structure and functions of coronavirus genomic 3' and 5'ends. Virus Res. 2015, 206, 120- 133.

[0359] 78. Vora, S.M.; Fontana, P ; Mao, T.; Leger, V.; Zhang, Y.; Fu, T.M.; Lieberman, J.; Gehrke, L.; Shi, M.; Wang, L.; et al. Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nspl evasion. Proc. Natl. Acad. Sci. USA 2022, 119, e2117198119.

[0360] 79. Sosnowski, P.; Tidu, A.; Eriani, G .; Westhof, E.; Martin, F. Correlated sequence signatures are present within the genomic 5'UTR RNA and NSP1 protein in coronaviruses. Rna 2022, 28, 729-741.

[0361] 80. Tidu, A.; Janvier, A.; Schaeffer, L.; Sosnowski, P .; Kuhn, L.; Hammann, P.; Westhof, E.; Eriani, G.; Martin, F. The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation. RNA 2020, 27, doi:10.1261 / ma.078121.120.

[0362] 81. Bujanic, L.; Shevchuk, O ; von Kugelgen, N.; Kalinina, A.; Ludwik, K.; Koppstein, D.; Zema, N.; Sickmann, A.; Chekulaeva, M. The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1 -mediated repression. RNA 2022, 28, 766-779.

[0363] 82. Lukavsky, P.J. Structure and function of HCV IRES domains. Virus Res. 2009, 139, 166-171.

[0364] 83. Fletcher, S.P.; Jackson, R.J. Pestivirus internal ribosome entry site (IRES) structure and function: Elements in the 5'untranslated region important for IRES function. J. Virol. 2002, 76, 5024- 5033.

[0365] 84. Gross, L.; Vicens, Q.; Einhorn, E.; Noireterre, A.; Schaeffer, L .; Kuhn, L.; Imler, J.L.; Eriani, G.; Meignin, C.; Martin, F. The IRES5'UTR of the dicistrovirus cricket paralysis virus is a type III IRES containing an essential pseudoknot structure. Nucleic Acids Res. 2017, 45, 8993-9004. 85. Femandez-Miragall, O.; Martinez-Salas, E. Structural organization of a viral IRES depends on the integrity of the GNRA motif. Rna 2003, 9, 1333-1344.

[0366] 86. Finkel, Y.; Mizrahi, O.; Nachshon, A.; Weingarten-Gabbay, S.; Morgenstem, D.; Yahalom-Ronen, Y .; Tamir, H.; Achdout, H.; Stein, D.; Israeli, O.; et al. The coding capacity of SARS- CoV-2. Nature 2021, 589, 125-130.

[0367] 87. de Breyne, S.; Chamond, N.; Decimo, D.; Trabaud, M.A.; Andre, P.; Sargueil, B.; Ohlmann, T. In vitro studies reveal that different modes of initiation on HIV-1 mRNA have different levels of requirement for eukaryotic initiation factor 4F. FEBS J. 2012, 279, 3098-3111.

[0368] 88. Dizin, E.; Gressier, C.; Magnard, C.; Ray, H ; Decimo, D.; Ohlmann, T.; Dalia Venezia, N. BRCA1 interacts with poly (A) -binding protein: Implication of BRCA1 in translation regulation. I Biol. Chem. 2006, 281, 24236-24246.

[0369] 89. Soto Rifo, R.; Ricci, E.P.; Decimo, D ; Moncorge, O.; Ohlmann, T. Back to basics: The untreated rabbit reticulocyte lysate as a competitive system to recapitulate cap / poly(A) synergy and the selective advantage of IRES-driven translation. Nucleic Acids Res. 2007, 35, el21.

[0370] 90. Jackson, R.J.; Hunt, T. Preparation and use of nuclease-treated rabbit reticulocyte lysates for the translation of eukaryotic messenger RNA. Methods Enzymol. 1983, 96, 50-74.

[0371] 91. Pelham, H R ; Jackson, R.J. An efficient mRNA-dependent translation system from reticulocyte lysates. Eur. J. Biochem. FEBS 1976, 67, 247-256.

[0372] 92. Waterhouse, A.M.; Procter, J.B.; Martin, D M.; Clamp, M.; Barton, G.J. Jalview Version 2— a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009, 25, 1189-1191.

[0373] 93. Deforges, J.; de Breyne, S.; Ameur, M.; Ulryck, N.; Chamond, N.; Saaidi, A.; Ponty, Y.; Ohlmann, T.; Sargueil, B. Two ribosome recruitment sites direct multiple translation events within HIV1 Gag open reading frame. Nucleic Acids Res. 2017, 45, 7382-7400.

[0374] 94. Rota, P.A ; Oberste, M.S.; Monroe, S.S.; Nix, W.A.; Campagnoli, R.; Icenogle, J.P.; Penaranda, S.; Bankamp, B.; Maher, K.; Chen, M.H.; et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300, 1394-1399.

[0375] 95. Marra, M.A.; Jones, S.J.; Astell, C.R.; Holt, R.A.; Brooks-Wilson, A.; Butterfield, Y.S.; Khattra, J.; Asano, J.K.; Barber, SA.; Chan, S.Y.; et al. The Genome sequence of the SARS-associated coronavirus. Science 2003, 300, 1399-1404.

[0376] 96. Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S.; Zaki, S.R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J.A.; Lim, W.; et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1953-1966.

[0377] 97. Bermingham, A.; Chand, M.A.; Brown, C.S.; Aarons, E.; Tong, C.; Langrish, C.; Hoschler, K.; Brown, K.; Galiano, M.; Myers, R.; et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012, 17, 20290.

[0378] 98. Lu, G.; Liu, D. SARS-like virus in the Middle East: A truly bat-related coronavirus causing human diseases. Protein Cell 2012, 3, 803-805.

[0379] 99. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367, 1814-1820.

[0380] 100. Senanayake, S.D.; Brian, D.A. Bovine coronavirus I protein synthesis follows ribosomal scanning on the bicistronic N mRNA. Virus Res. 1997, 48, 101-105.

[0381] 101. Senanayake, S.D.; Brian, D.A. Translation from the 5' untranslated region (UTR) of mRNA 1 is repressed, butthat from the 5' UTR of mRNA 7 is stimulated in coronavirus-infected cells. J. Virol. 1999, 73, 8003-8009.

[0382] 102. Muller, C.; Schulte, F.W.; Lange-Grunweller, K.; Obermann, W.; Madhugiri, R.; Pleschka, S.; Ziebuhr, J.; Hartmann, R.K.; Grunweller, A. Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picomaviruses. Antivir. Res. 2018, 150, 123-129.

[0383] 103. Cencic, R ; Desforges, M.; Hall, D.R.; Kozakov, D.; Du, Y.; Min, J.; Dingledine, R.; Fu, H.; Vajda, S.; Talbot, P.J.; et al. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J. Virol. 2011, 85, 6381-6389.

[0384] 104. Jackson, R.J.; Hunt, S.L.; Reynolds, J.E.; Kaminski, A. Cap-dependent and capindependenttranslation: Operational distinctions and mechanistic interpretations. Curr. Top. Microbiol. Immunol. 1995, 203, 1-29.

[0385] 105. Ohlmann, T.; Rau, M. ; Morley, S. ; Pain, V.M. Effect of cleavage of the p220 subunit of eukaryotic translation initiation factor eIF-4F on protein synthesis in vitro. Biochem. Soc. Trans. 1995, 23, 315S.

[0386] 106. Ohlmann, T.; Rau, M.; Morley, S.J.; Pain, V.M. Proteolytic cleavage ofinitiation factor eIF-4 gamma in the reticulocyte lysate inhibits translation of capped mRNAs but enhances that of uncapped mRNAs. Nucleic Acids Res. 1995, 23, 334-340.

[0387] 107. Prevot, D.; Darlix, J.L.; Ohlmann, T. Conducting the initiation of protein synthesis: The role of eIF4G. Biol. Cell Under Auspices Eur. Cell Biol. Organ. 2003, 95, 141-156.

[0388] 108. Borman, A.M.; Kirchweger, R.; Ziegler, E.; Rhoads, R.E.; Skem, T.; Kean, K.M. eIF4G and its proteolytic cleavage products: Effect on initiation of protein synthesis from capped, uncapped, and IRES-containing mRNAs. Rna-A Publ. Rna Soc. 1997, 3, 186-196.

[0389] 109. Linder, P.; Fuller-Pace, F.V. The biology of RNA helicases- modulation for life. Preface. Biochim. Biophys. Acta 2013, 1829, 749.

[0390] 110. Cencic, R.; Pelletier, J. Hippuristanol — A potent steroid inhibitor of eukaryotic initiation factor 4A. Translation 2016, 4, el 137381. 111. Pestova, T V.; Shatsky, LN.; Fletcher, S.P.; Jackson, R.J.; Hellen, C.U. A prokaryotic- like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev. 1998, 12, 67-83.

[0391] 112. Morris, D.R.; Geballe, A.P. Upstream open reading frames as regulators of mRNA translation. Mol. Cell. Biol. 2000, 20, 8635-8642.

[0392] 113. Calvo, S.E.; Pagliarini, D.J.; Mootha, V.K. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. Proc. Natl. Acad. Sci. USA 2009, 106, 7507-7512.

[0393] 114. Silva, J.; Fernandes, R.; Romao, L. Translational Regulation by Upstream Open Reading Frames and Human Diseases. Adv. Exp. Med. Biol. 2019, 1157, 99-116.

[0394] 115. Zhang, H.; Wang, Y.; Lu, J. Function and Evolution of Upstream ORFs in Eukaryotes. Trends Biochem. Sci. 2019, 44, 782-794.

[0395] 116. Spriggs, K.A.; Bushell, M.; Willis, A.E. Translational regulation of gene expression during conditions of cell stress. Mol. Cell 2010, 40, 228-237.

[0396] 117. Young, S.K.; Wek, R.C. Upstream Open Reading Frames Differentially Regulate Genespecific Translation in the Integrated Stress Response. J. Biol. Chem. 2016, 291, 16927-16935.

[0397] 118. Berry, K E ; Waghray, S.; Mortimer, S.A.; Bai, Y.; Doudna, J A. Crystal structure of the HCV IRES central domain reveals strategy for start-codon positioning. Structure 2011, 19, 1456— 1466.

[0398] 119. Haimov, O.; Sinvani, H.; Dikstein, R. Cap-dependent, scanning-free translation initiation mechanisms. Biochim. Biophys. Acta 2015, 1849, 1313-1318.

[0399] 120. Futterer, J.; Kiss-Laszlo, Z.; Hohn, T. Nonlinear ribosome migration on cauliflower mosaic virus 35S RNA. Cell 1993, 73, 789-802.

[0400] 121. Sorokin, I.I.; Vassilenko, K.S.; Terenin, I.M.; Kalinina, N.O.; Agol, V.I.; Dmitriev, S.E. Non-Canonical Translation Initiation Mechanisms Employed by Eukaryotic Viral mRNAs. Biochemistry 2021, 86, 1060-1094.

[0401] 122. Tarun, S.Z., Jr.; Sachs, A.B. Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G. EMBO J. 1996, 15, 7168-7177.

[0402] 123. Imataka, H.; Gradi, A.; Sonenberg, N. A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and functions in poly(A)-dependent translation. EMBO J. 1998, 17, 7480-7489.

[0403] 124. Kahvejian, A.; Roy, G.; Sonenberg, N. The mRNA closed-loop model: The function of PABP and PABP-interacting proteins in mRNA translation. Cold Spring Harb. Symp. Quant. Biol. 2001, 66, 293-300. 125. Jacobson, A. Poly(A) Metabolism and Translation: The Closed-loop Model. In Translational Control; Hershey, J.W.B.M., Sonenberg, N.M.B., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring, NY, USA, 1996; pp. 451-480.

[0404] 126. Gallic, D.R. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 1991, 5, 2108-2116.

[0405] 127. Poncet, D.; Laurent, S.; Cohen, J. Four nucleotides are the minimal requirement for RNA recognition by rotavirus non-structural protein NSP3. EMBO J. 1994, 13, 4165-4173.

[0406] 128. Vende, P.; Piron, M.; Castagne, N.; Poncet, D. Efficient translation of rotavirus mRNA requires simultaneous interaction of NSP3 with the eukaryotic translation initiation factor eIF4G and the mRNA 37end. J. Virol. 2000, 74, 7064-7071.

[0407] 129. Graft, C.M.; Burley, S.K. Recognition of eIF4G by rotavirus NSP3 reveals a basis for mRNA circularization. Mol Cell 2002, 9, 1273-1283.

[0408] 130. Michel, Y.M.; Borman, A.M.; Paulous, S.; Kean, K.M. Eukaryotic initiation factor 4G- poly(A) binding protein interaction is required for poly(A) tail-mediated stimulation of picomavirus internal ribosome entry segment-driven translation but not for X-mediated stimulation of hepatitis C virus translation. Mol. Cell. Biol. 2001, 21, 4097-4109.

[0409] 131. von Moeller, H.; Lerner, R.; Ricciardi, A.; Basquin, C.; Marzluff, W.F.; Conti, E. Structural and biochemical studies of SLIP1-SLBP identify DBP5 and eIF3g as SLIP 1 -binding proteins. Nucleic Acids Res. 2013, 41, 7960-7971.

[0410] 132. Neusiedler, J.; Mocquet, V.; Limousin, T.; Ohlmann, T.; Morris, C.; Jalinot, P. INT6 interacts with MIF4GD / SLIP1 and is necessary for efficient histone mRNA translation. Rna 2012, 18, 1163-1177.

[0411] 133. Wu, H.Y.; Ke, T.Y.; Liao, W.Y.; Chang, N.Y. Regulation of coronaviral poly(A) tail length during infection. PLoS ONE 2013, 8, e70548.

[0412] 134. Teixeira, F.K.; Lehmann, R. Translational Control during Developmental Transitions. Cold Spring Harb. Perspect. Biol. 2019, 11, a032987.

[0413] 135. Thoms, M.; Buschauer, R.; Ameismeier, M.; Koepke, L.; Denk, T.; Hirschenberger, M.; Kratzat, H.; Hayn, M.; Mackens-Kiani, T.; Cheng, J.; et al. Structural basis for translational shutdown and immune evasion by the Nspl protein of SARS-CoV-2. Science 2020, 369, 1249-1255.

[0414] 136. Schubert, K ; Karousis, E D ; Jomaa, A.; Scaiola, A.; Echeverria, B.; Gurzeler, L.A.; Leibundgut, M ; Thiel, V.; Muhlemann, O.; Ban, N. SARS-CoV-2 Nspl binds the ribosomal mRNA channel to inhibit translation. Nat. Struct. Mol. Biol. 2020, 27, 956-966.

[0415] 137. Baneqee, A.K.; Blanco, M.R.; Bruce, E.A.; Honson, D.D.; Chen, L.M.; Chow, A.; Bhat, P.; Ollikainen, N.; Quinodoz, S.A.; Loney, C.; et al. SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. Cell 2020, 183, 1325-1339. e21. 138. Vankadari, N.; Jeyasankar, N.N.; Lopes, W.J. Structure of the SARS-CoV-2 Nspl / 5'- Untranslated Region Complex and Implications for Potential Therapeutic Targets, a Vaccine, and Virulence. J. Phys. Chem. Lett. 2020, 11, 9659-9668.

[0416] 139. Ingolia, N.T.; Ghaemmaghami, S.; Newman, J.R.; Weissman, J.S. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profding. Science 2009, 324,

[0417] 218-223.

[0418] 140. Lee, S.; Liu, B ; Lee, S.; Huang, S.X.; Shen, B.; Qian, S.B. Global mapping of translation initiation sites in mammalian cells at single-nucleotide resolution. Proc. Natl. Acad. Sci. USA 2012, 109, E2424-32. 141. Wright, B.W.; Yi, Z Weissman, J.S.; Chen, J. The dark proteome: Translation from noncanonical open reading frames. Trends Cell Biol. 2022, 32, 243-258.

[0419] 142. Wu, H.Y.; Guan, B.J.; Su, Y.P.; Fan, Y.H.; Brian, D.A. Reselection of a genomic upstream open reading frame in mouse hepatitis coronavirus 5 '-untranslated-region mutants. J. Virol. 2014, 88, 846-858. 143. Irigoyen, N.; Firth, A.E.; Jones, J.D.; Chung, B.Y.; Siddell, S.G.; Brierley, I. High-

[0420] Resolution Analysis of Coronavirus Gene Expression by RNA Sequencing and Ribosome Profiling. PLoS Pathog. 2016, 12, el005473.

[0421] file: / / it-file02.inserm.dom / DATAS / DETECTION PROTECTION / DOSSIERS / O / OHLMANN23015 / TEXTE DE BREVET / PRIORITE / DEPOT / sequenc...

Claims

CLAIMS:

1. . An isolated RNA molecule comprising(a) a coding region, including a start codon at its 5' end, coding for a polypeptide; and(b) directly upstream of said coding sequence a 5’UTR sequence comprising a SARS-COV2 LEADER SEQUENCE (called LS) of SEQ ID N°1 : AUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUC UCUUGUAGAUCUGUUCUCUAAACGAAC wherein the RNA molecule comprises optionally a poly-A tail at the 3' end.

2. . The RNA molecule according to claim 1 wherein said 5’UTR is selected from the group consisting of:(bl ) an UTR of the sequence : LS (SEQ ID NO:1 )(b2) an UTR of the sequence LS-A (SEQ ID NO:2)(b3) an UTR of the sequence LS- AAACTAAA (AAACUAAA) (SEQ ID NO:3) (ORF N);(b4) an UTR of the sequence LS UUUACUCUCCAAUUUUUCUUAUUGUUGCGGCAAUAGUGUUUAUAACA CUUUGCUUCACACUCAAAAGAAAGACAGA (SEQ ID NO: 4);(b5) an UTR of the sequence LS- GCUUUCUUAUUACAAAUUGGGAGCUUCGCAGCGUGUAGCAGGUGACU CAGGUUUUGCUGCAUACAGUCGCUACAGGAUUGGCAACUAUAAAUUA AACACAGACCAUUCCAGUAGCAGUGACAAUAUUGCUUUGCUUGUACAGUAAGUGACAACAG (SEQ ID NO: 5);(b6) an UTR of the sequence LS- UAAAUAUUAUAUUAGUUUUUCUGUUUGGAACUUUAAUUUUAGCC (SEQ ID N0:6); and(b7) an UTR of the sequence LS- TT (-UU) (SEQ ID NO:7);(b8) an UTR of the sequence LS- UUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCAC GCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAA CUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCC GAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAG (SEQ ID NO: 8); and or a sequence wherein in said UTR sequence the triplet AUG at position 107- 109 of SEQ ID NO: 8 is substituted by a triplet different from AUG and / or at least one triplet UAA or UGA at position 134-136; 137-139; 251-253; and 262-264 of of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA, UAG, UGA (stop codon); and(b9) an UTR sequence substantially homologous to the sequence of (bl) to (b8) preferably an sequence at least 80% identical to the sequence of (bl) to (b8).

3. The RNA molecule according to claim 2, wherein the triplet AUG at position 107- 109 of SEQ ID NO:8 is substituted by a triplet UAA or UUG or CCG.

4. The RNA molecule according to claim 2 or 3 wherein, at least one of the triplet UAA or UGA at position 134-136; 137-139; 251-253; and 262-264 of SEQ ID NO:8 is deleted or substituted by a triplet different from UAA, UAG, UGA (stop codon). .

5. The RNA molecule according to any one of claims 1 to 4, wherein the poly-A tail has a length of at least 50 nucleotides.

6. A nucleic acid molecule encoding the RNA molecule of any one of claims 1 to 5.

7. A vector comprising the nucleic acid molecule of claim 6 or the RNA molecule according claim 1 to 5.

8. A host cell comprising the vector of claim 7.

9. A pharmaceutical composition comprising the RNA molecule according to any one of claims 1 to 5, the nucleic acid molecule according to claim 6 , the vector according to claim 7 or the host cell according to claim 8 and optionally a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 8 for use in RNA-based therapies.

11. A vaccinal composition comprising the RNA molecule according to any one of claims 1 to 5, the nucleic acid molecule according to claim 6 , the vector according to claim 7 or the host cell according to claim 8 and optionally an immunoadjuvant.

12. The vaccinal composition of claim 10 for use in RNA-based vaccination.

13. A kit comprising the RNA molecule according to any one of claims 1 to 4, the nucleic acid molecule according to claim 6 , the vector according to claim 7 or the host cell according to claim 8.

14. Use of an UTR as defined in claim 1 to 3 for translating a coding region of RNA molecule into a polypeptide or a protein encoded by said coding region.

15. An in vitro method for translating a coding region of RNA molecule into a polypeptide or a protein encoded by said coding region using an 5’UTR as defined in claim 1 to 5.

Citation Information

Patent Citations

  • Aminoalcohol lipidoids and uses thereof

    US8450298B2

  • Method for inhibiting the expression of a target gene

    WO2002055693A2

  • RNA containing modified nucleosides and methods of use thereof

    WO2007024708A2

  • Improved 5 'UTR and 3' UTR based on coronavirus genome and application of improved 5 'UTR and 3' UTR

    CN116144651A

  • SARS-CoV-2 VACCINES USING A LIVE ATTENUATED VIRUS

    WO2022103870A1